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ABSTRACT

Over 350,000 artificial heart valves are implanted each year domestically in the US
due to valvular stenosis, regurgitation, or congenital defects. However, worldwide, there
is precipitous demand of artificial heart valves in emerging economies and this demand is
in younger populations because the need for artificial valves in these regions are driven
by disease states such as rheumatic fever. With the increasing demand on this life
sustaining device, a more robust and durable biomaterial with higher implant life is
necessary for increased patient patency and quality of life.
Current heart valve replacements only last 10-15 years before implant failure occurs.
These replacements fail primarily due to structural degradation through wear and tear
(leading to regurgitation) and/or calcification (leading to stenosis). Therefore, we have
developed a novel fabrication method that produces a more durable material that is
structurally more stable and resists calcification. Furthermore, through the use of this
novel fabrication method, we have been able to study mechanistically the underlying
factors in failure modes of current biomaterials used in bioprosthetic heart valve
fabrication that lead to structural degradation and calcificaiton. Through the analyses of
investigating potential failure modes, we are able to better strategically approach
improving the next iteration of bioprosthetic heart valve materials that can significantly
improve current patient segment quality of life as well as give healthcare options to those
currently underserved in the bioprosthetic heart valve market.
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CHAPTER ONE
1. LITERATURE REVIEW
1.1

Valve Disease and Patient Demographic

Over 300,000 artificial heart valves are implanted each year domestically in the US
due to valvular stenosis, regurgitation, or congenital defects [1-3]. By 2050, this volume
is expected to increase to 850,000 annually just within the US [4]. However, worldwide,
there is precipitous demand of artificial heart valves in emerging economies and this
demand is in younger populations because the need for artificial valves in these regions
are driven by disease states such as rheumatic fever [2-4]. However, current 12% of heart
valve replacements (HVRs) require reoperation by five years [5]. Furthermore, HVRs
options are more limited for patients younger than 55 and some options seem to fail faster
in younger patients [5-8]. With the increasing demand on this life sustaining device, a
more robust and durable biomaterial with higher implant life is necessary for increased
patient patency and quality of life.

1.1.1

Current target patient segments

Over 300,000 heart valve replacements occur each year within the US alone [9].
Developing countries could have as many as 2MIL+ patients needing replacements right
this instant that are predominantly in the young patient segment [4]. The preferred option
for heart valve replacement is bioprosthetic heart valves (BHVs).
The use of BHVs within the US has increased from 37.7% in 1998-2001 to 63.6%
in 2007-2011 [10]. The 50% failure rate in BHVs within recipients aged 60-75 is 18.5
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years however the 5% failure rate is around 10-12 years [5] with younger patient
demographics showing accelerated failure rates [5, 8]. These survival curves are depicted
in Figure 1-1.

Figure 1-1. Kaplan-Meier freedom from structural valve deterioration (SVD) by age
groups [5].
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1.2

Basic Cardiac Anatomy

The cardiovascular system functions in supplying the cells of the body with
nutrients and carrying away wastes for excretion and expiration. The blood, comprised of
proteins and plasma, serves as the vehicle for these nutrients and wastes, the vessels as
the highways, and at the center of the entire cardiovascular system is the heart driving
this extensive delivery and excretion system. Below, figure 1-2 shows the fundamental
processes of nutrient exchange and delivery of the cardiovascular system.

Figure 1-2. Simple schematic fundamental anatomy and physiology of the cardiovascular
system. (http://www.freerider.ro/sanatate/ce-puls-ai-98114.html)
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1.2.1

Heart anatomy

The heart is a synchronized two pump system that utilizes the contraction of
chamber walls and valves to create a pressure gradient that drives the fluid flow through
blood vessels. The right side of the heart circulates blood to the lungs (pulmonary
system) and the left side supplies the rest of the body (systemic) with oxygen rich blood.
Figure 1-3 depicts the basic anatomy of a heart. Figure 1-4 depicts basic heart function.
During ventricular diastole, blood flows through the atrioventricular valves to fill the
ventricles. During ventricular systole, the ventricular walls contract to force blood
through the pulmonary and aortic valve to pulmonic and systemic circulation,
respectively. Any abnormalities in the contraction of cardiac muscle or valve function
will result in insufficient nutrient and waste exchange at the cellular level throughout the
body. Therefore, the dysfunction of any cardiac tissue warrants a serious and aggressive
treatment to deal with pathologies because the patient can be compromised so easily.

4

Figure 1-3. Basic anatomy of a heart. (https://ufhealth.org/heart-valve-surgery)
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Figure 1-4. Blood flow (red arrows) through the heart during ventricular diastole (left)
and ventricular systole (right). (http://www.freerider.ro/sanatate/ce-puls-ai-98114.html)

1.2.2

Overview of heart valve

There are four valves within the heart and have contrasting structures based on the
function required of the valve. The location and gross anatomy of these four main valves
are depicted in figure 1-4. Valves are the barriers separating blood from the four
chambers of the heart. They are the doors in which blood must pass through before it
journeys to the rest of the body. These are regions of pressure differentials that are
separated by a thin piece of soft connective tissue. Valves exist to keep blood
compartmentalized and efficiently transported. The pulsatile nature of the cardiovascular
system is essential because of the time requirement of nutrient exchange in capillaries
and thus hinges on heart valves functioning correctly.
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Figure

1-5.

The

four

valves

of

the

heart.

(http://www.cts.usc.edu/hpg-

valvesoftheheart.html)
The location, arrangement, and composition of these soft connective tissue
structures give rise to the four different valves of the heart – the aortic valve, pulmonary
valve, and two mitral valves located between each atrium and ventricle. This literature
review will focus on the aortic valve that functions between the left ventricle and aorta. It
is the doorway blood passes through from the heart to the rest of the body. Mechanical
function of the native aortic valve is illustrated in Figure 1-6.
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Figure 1-6. Mechanical function of the aortic heart valve. (A) Valve physiology as
pressures change within the ventricle. (B) Biomechanical response of native and fixed
valves. (C) Gross anatomy of valve in open (left) and closed (right) position. [11]
The aortic heart valve has three leaflets – one non coronary leaflet and two
coronary leaflets – arranged in a circle like a pie being cut into thirds. It is important to
note that the non-coronary artery does not have a sinus like the right and left anterior
leaflets thereby creating a different flow pattern than the other two leaflets. These leaflets
are very thin and are viscoelastic in nature and are extensions of the fibrous skeleton.
They are attached via a fibrous ring called the annulus [12-14]. When the valve leaflets
are in the closed position and the edges of the leaflets are touching, they are said to be in
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“coaptation.” In this native resting state, the leaflets sag towards ventricle side. This
allows the valve to be a one way only valve to prevent backflow during ventricular
filling. As blood enters the left ventricle, the pressure in the aorta exceeds that of the left
ventricle thus closing the valve (coaptation). During ventricular contraction (systole), the
pressure in the left ventricle exceeds that of the aorta causing the leaflets to collapse to
the aortic wall opening up an orifice for blood to flow. Often times, this effective orifice
area (EOA) is used as a clinical metric to gauge heart valve health.
The pressure differentials across the valves experience some of the highest
pressures within the body and these valves are able to produce pulsatile flow throughout
the body because of the way they function. Furthermore, the heart valve tissue undergoes
approximately 3.2 billion cycles of high pressure differentials in an average human
lifespan making the heart valve one of the most difficult tissues to replace.

1.2.3

Valve leaflet anatomy

The functional subunit of the aortic heart valve is the valve leaflet. The aortic
heart valve has three leaflets arranged radially around a center point resembling a
Mercedes emblem. Each leaflet has a semispherical geometry with a radius of ~10mm.
The leaflet is about ~1-2mm thick and stratifies into three distinct layers. Figure 1-7
depicts the gross anatomy of an aortic heart valve leaflet. The fibriosa is the superior
most layer bordering the aorta. The fibriosa contains radially aligned collagen and
functions mainly in structural strength. The inferior most layer is the ventricularis
bordering the ventricular side. The ventricularis is mainly composed of radially aligned
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collagen and circumferentially aligned elastin and functions in giving the tissue
composite elasticity and recoil. In between the fibriousa and ventricularis is the
spongiosa. This layer is mainly comprised of glycosaminoglycans (GAGs) which
function in providing a gel-like layer that is believed to provide shock absorption for the
tissue. GAGs also play many biological roles and passively draws in water to give rise to
the viscoelastic behavior of the leaflet tissue. The leaflet as a whole is avascular and is
considered a connective tissue. Vascular interstitial cells are the proliferating cell line that
gives rise to this complex, highly customized ECM. Given the size, geometry, stresses
sustained, and high cyclic lifespan of the human aortic heart valve, it is one of the hardest
tissues to replace.

Radial
Circumferential
Figure 1-7. Gross valve leaflet anatomy with orientation [15].

1.2.4

Valve leaflet components and function

As mentioned before in previous sections, heart valve leaflets are soft connective
tissues. Therefore, they are comprised of three main components in their extracellular
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matrix – collagen, GAGs, and elastin. The integrity of the valve rests on maintaining the
integrity of these ECM components as loss of any of the ECM components have been
previously demonstrated to greatly adversely affect valve function [15-22].

Collagen is the main structural, load bearing component [16]. Collagen itself is a
multiscale protein in the sense that it has repeated structural organization. Individual
collagen fibers are staggered segments of glycine-, proline-, and hydroxyproline- rich
tropocollagen macromolecules that are wrapped into triple helix structures. The small
residue amino acid composition of these tropocollagen macromolecules are vital to the
tight wrapping of this triple helix structure that allows for extensibility as well as load
bearing capabilities [23, 24]. Collagen fibers are then bundled together and staggered to
form collagen bundles which are then grouped together. At the macro level, collagen has
an inherent crimp that allows the macrobody have even more extensibility than the
individual collagen triple helice subunits. Figure 1-8 illustrates this hierarchy of anatomy
to produce functional collagen. This structure allows much load bearing per mass of
protein with viscoelastic properties. Taking out collagen of leaflet tissues is noted by a
complete detrimental loss of almost all biomechanical function and load bearing ability.
Approximately 55% of the dry mass of aortic valve leaflet tissue is comprised of collagen
[25].

11

Figure 1-8. Multiscale breakdown of anatomical structure of functional collagen fibers
(http://www.proto-col.com/blog/2014/07/collagen/).
There are multiple types of collagen (types I – V) that are customized to where
they are used within the body. Type I and III are the most abundantly found collagen
types within heart valves [23, 24]. Collagen is found throughout the entire valve in all
three layers however the fibrosa is mainly composed of collagen. This is due to the high
amount of forces localized to this region of the valve leaflet during heart valve function.
The fibrosa anchors directly to a fibrous ring around the aortic wall [14]. The collagen is
also aligned in the circumferencial direction of the valve leaflet to efficiently bare loads
[13].
Another main component of the ECM of valve leaflets are glycosaminoglycans
(GAGs). There are many types of GAGs but they are all composed of long, unbranched
polysaccharides consisting of repeating disaccharide units. Each subunit of a GAG
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contains an amino acid sugar and an uronic acid group [26]. The four types of GAGs
relevant to heart valve leaflet anatomy are (1) chondroitin sulfate, (2) dermatan sulfate,
(3) keratin sulfate, and (4) hyaluronan. These basic building blocks of GAGs are depicted
in figure 1-9. Though GAGs comprise a very small percentage of the total weight or
protein content within the leaflet tissue, they play a major role in organizing the tissue as
they are spread throughout the ECM.

Figure 1-9. Chemical structures of basic GAGs found in soft connective tissue
(http://chemistry.tutorvista.com/organic-chemistry/glycosaminoglycans.html).

13

Figure

1-10.

Structure

of

proteoglycan

aggregate

(A)

electron

microscopy

photomicrograph [31], (B) diagram of proteoglycan aggregate structure and key elements
[32].
Figure 1-9 depicts how the hyaluronan chain serves as the backbone and other
GAGs can modularly branch off of this hyaluronan backbone much like polymer
branches. Through this modularity, GAGs can be built into different variations of ground
substance to create different hydrophilic environments. This is why GAGs are believed to
primarily comprise the spongiosa of the valve leaflet. GAGs allow the passive flow of
water to create a hydrogel like layer between the fibrosa and ventricularis. This allows
the tissue to withstand large amounts of shear through the tissue. GAGs also play a role
in fiber-fiber orientation as well as a biomechanical role in low force tension [16, 27].
This is thought to prevent “fluttering” of the leaflets for smooth coaptation of the leaflets.
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When GAGs are removed are left unstabilized long term, it has been previously
demonstrated that leaflet tissues buckle when subjected to bending [28]. Furthermore, it
has previously been demonstrated that long term cycling of valves results in GAG loss
and a notable loss in leaflet bending stiffness [29].
The final main component of the ECM is elastin, a fibriller protein that creates a
fibrous network of intercrosslinked subunits that have exceptionally high degrees of
extensibility. Elastin can be strained up to 150% of its nominal length without fiber
failure. This is accomplished in the microscrutural subunit of tropoelastin as well as the
macrostructural crosslinking of these subunits. Elastin contains high amounts of
hydrophobic residues including alanine, lysine, glycine, valine, and proline [30, 31].
Alanine and lysine rich portions of elastin form alpha helices. The glycine, valine, and
proline rich portions form beta sheets [32, 33]. The key in orienting these alpha helices
around the beta sheets such that the beta sheets are protected is through the strategic
placement of lysine residues. When elastin is formed, these lysine residues are
crosslinked by lysol oxidase through deamination reactions to form desomsine,
isodesmosine, and lysinonorleucine. Through these crosslinked, tropoelastin subunits are
crosslinked into an interconnected mesh network. Figure 1-11 depicts the protein
structure of elastin and how elastin is crosslinked together.
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Figure 1-11. Structural domains of elastin, demonstrating repeat units of α-helix
hydrophilic domains and β-strand hydrophobic domains. Elastin is naturally crosslinked
by desmosine crosslinks, indicated by –X – [34].
With regards to heart valve leaflets, elastin provides the ability of the valve leaflet
tissue to remain extensible and return to the resting position during diastole. This is
accomplished through the structure of elastin. Applying an axial load to this
interconnected body causes realignment of all the tropoelastin molecules that are still
held together through the crosslinks. Release from this axial tension causes the crosslinks
to realign the tropoelastin molecules back to their original positions. Figure 1-12
illustrates how elastin undergoes large increases in strain and is still able to return back to
nominal gauge length once it is released from tension. Because elastin is highly localized
to the ventriularis of the valve leaflet and radially aligned, it allows for elastin to return
the leaflet to the resting, coaptation position.
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Figure

1-12.

Microstructure

of

fibrous

elastin

in

stretch

and

relaxation

(http://www.iib.unsam.edu.ar/php/docencia/licenciatura/biotecnologia/2012/BioCel/Clase
02.pdf)
The aortic valve leaflet is composed of ~13% elastin by dry weight. Unlike
collagen and GAGs, elastin does not undergo much metabolic turnover and the
maintenance of elastin slowly goes away as humans age [35]. Eliminating elastin from
the leaflet tissue results in large deviations from native behavior. A loss of almost all
extensibility is noted [15, 18, 35]. This would physiologically manifest as a valve that
cannot effectively return to coaptaion during cardiac systole.
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All ECM components are maintained and overturned by valvular interstitial cells
(VICs) in native valves. GAG turnover is common. Collagen turnover is on an as needed
basis. Elastin is seldomly turned over. It should be noted that heart valve replacements do
not have viable cells and therefore ECM turnover does not exist.
Depending on the environmental stimuli, VICs can either exist as activated VICs
(aVICs) or quiescent VICs (qVICs). VIC activity has become a topic of interest recently,
specifically the activation or suppression of VIC activity. If VICs are not able to maintain
the delicate microstructure of the leaflet anatomy through native deficiencies or external
factors, the result will more than likely be some type of valvular disease requiring
intervention later on.

1.3

Valve Disease Pathology

Valvular disease presents symptomatically with shortness of breath, especially
when exercising, chest pain, lightheadedness, fainting, fatigue, and heart murmurs. These
all arise due to partial compromise in normal systemic blood flow from the heart valve
not opening/closing properly. If left untreated, valvular disease can be fatal.
Valvular disease can be broken down into valve stenosis or valve insufficiency.
Figure 1-13 summarizes the gross overview of normal native heart valve function
compared to that of valves affected by degenerative heart valve disease. Valve stenosis
results in a reduced cross sectional area in which blood can flow through the valve.
Insufficiency arises when the valve leaflets do not coapt together during systole resulting
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in backflow of blood. However, there are multiple causes to cause stenosis or valve
insufficiency.

Figure 1-13. Gross overview of normal aortic heart valve compared to degenerative
aortic heart valve diseases resulting in conditions necessitating an HVR. (Left top)
Normal effective orifice area during ventricular systole. (Left bottom) Normal coaptation
of heart valve leaflets during ventricular diastole. (Right Top) Stenotic valve that cannot
open into optimal effective orifice area during ventricular systole. (Right Bottom)
Regurgitant heart valve from heart valve leaflets not being able to accomplish coaptation
during diastole [12].
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Figure 1-14. Healthy native aortic heart valve compared to calcified native heart valve.
(Left) Healthy human aortic valve [36] and (Right) explanted calcified human aortic
valve with arrow pointing to calcific nodule [37].
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Valve stenosis is most commonly caused by calcification nodules developing
from within the valve leaflets and accumulating more and more mineralization over time.
Figure 1-14 is a gross overview comparison of a healthy native aortic valve with a
calcified native aortic heart valve. This causes stiffening of the valve leaflet accompanied
by highly fibrotic tissue thereby reducing the operational range of motion in which the
valve leaflet moves [38-41]. This predominantly happens in more elderly patients aged
65 or older.
Reduced effective orifice area and/or stiffened leaflets mean that the heart must
pump harder generating larger pressure gradients across the aortic valve. This can
overwork the heart itself, reduce systemic blood flow, and calcification deposits can
break off and embolize in other parts of the body such as the coronary artery or the brain
causing heart attack or stroke, respectively.
Other contributing causes and factors to valve disease include congenital defects
at birth, other diseases that compromise ECM proteins in the heart such as rheumatic
fever and infective endocarditis, or degenerative processes that occur as individuals age
that result in structural degradation or calcific degradation. These disease conditions
predominantly present themselves in the systemic side (non-pulmonic, left side) of the
heart where pressures are much greater. Therefore, the majority of disease pathologies are
isolated to the aortic and mitral valves.
Rheumatic fever is an inflammatory disease that develops from a complication
with strep throat or scarlet fever, both caused by Streptococcus bacteria. Most often this
is caused by inadequate treatment of the initial contracted disease. This occurs
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predominantly in children and sometimes young adults. Rheumatic fever can develop into
rheumatic heart disease resulting in damaged heart valves and even heart failure. Though
there are minimal cases in the US and developed countries, it is still common in
underserved markets around the world [42-47] as depicted by figure 1-15.

Figure 1-15. Prevalence and shifts in incidence of rheumatic fever throughout the world
[46].
Infective endocarditis is defined as the infection and vegetation of the
endocardium of the heart valves [48-51]. Most infective endocarditis cases are caused by
Streptococcus aureus or Streptococcus epidermis. Because other pathologies such as
rheumatic fever or native compromising of bacterial resistance promote infective
endocarditis, infective endocarditis often accompanies other pathologies and exacerbates
tissue destruction.
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Because valve leaflets lack vasculature, initial infection must originate from the
blood itself. Therefore, native imperfections in the heart valve leaflet or already damaged
valves are often accompanied by infective endocarditis because bacteria or fungi may
lodge itself into damaged areas of the valve. These bacteria or fungi cause tissue
destruction during the repair process within the damaged ECM and develop into larger
and larger vegetations. This results in either leaflet destruction resulting in insufficiencies
or thickening of the valve leaflets resulting in stenosis [52]. This further complicates
other valve pathologies that may be at play due to the degenerative outcomes of infection.
The tissue damage done by the bacteria promotes even more bacterial attachment further
degrading the tissue faster and will most likely work synergistically with other
pathologies to accelerate heart valve failure.
Congenital defects or preexisting conditions (not acquired pathologies like
rheumatic fever or infective endocarditis) within the heart valve can also give rise to
valve stenosis or insufficiency. Congenital defects affect 3% of the population and most
congenital defects go undetected until routine examination. The predominant congenital
defects seen in valves are myxomatous valves or bicuspid aortic valves [13, 53]. Other
preexisting conditions that can compromise valve longevity are autoimmune diseases that
can use the body’s own immune system to destroy its own tissue or other pathologies that
result in connective tissue disorders (ie. diabetes patients that have collagen defects).
Myxomatous valves are prolapsed valves that have reduced bending stiffness.
They are commonly referred to as “floppy valves.” These valves do not have adequate
coaptation resulting in regurgitant bloodflow. This reduction in bending stiffness is
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caused by a thickened spongiousa layer due to an increased accumulation of dermatin
sulfate [13, 20, 54, 55]. This weakens the fibrosa layer that is meant to bare most of the
load during heart valve function by pushing apart the collagen bundles [54].
Bicuspid aortic valves appear to have only two leaflets in the aortic position. This
can present as two of the three leaflets fused together or two symmetric leaflets. Having
this valve structure is usually asymptomatic and will most likely go undiagnosed until
examination during early life. However, bicuspid aortic valves can lead to aortic root
dilation or leaflet prolapse later on in life if left untreated [54] [53].
Other factors contributing to native valve disease and failure are passive
degenerative processes that cause structural degradation or calcification within the valve
tissue. These degenerative processes predominantly affect the elderly population and
comprise main patient demographic within developed countries of heart valve
replacement recipients [47]. Preexisting conditions predispose individuals to valve
degeneration and may accelerate valve degeneration processes [13, 40, 41, 47, 54]. Aortic
schlerosis is often a cofactor in degenerative heart valve disease and progresses much like
atheroschlerosis [13, 40, 41]. These pathologies are often associated with, predominantly,
lifestyle choices given no preexisting conditions. Recent research has also demonstrated
that phenotypic shifts in VICs may also contribute to active calcification processes.
Increased macrophage activity may induce VICs to switch to more osteoblast-like
behavior resulting in bone-like mineralization [13, 40, 41, 56-58].
Though there are innovations in heart valve replacements, much research has been
in preventative treatment to treat heart valve disease. Furthermore, there may be common
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pathways between native valve failure and heart valve replacement failure as they share
many parallels.

1.4

Treatment Options

Depending on when and how much the valvular disease or degeneration has
progressed dictates how much and what type of intervention is necessary to treat the
patient. Therefore, treating valvular disease is highly case dependent. Ultimately, it is the
clinician’s goal to improve the patient’s life in the context of their lifestyle.
To determine what level of intervention or treatment is necessary, healthcare
providers use a multitude of metrics to assess the performance of the native heart valve.
Through the use of these metrics, they attempt to as accurately as possible measure the
added value to the patient versus the risk of the procedure required to better those
metrics. Therefore, proper assessment using diagnostic metrics are utilized before
determining which treatment option is appropriate.
Noninvasive visualization techniques can be utilized to determine if valve disease
is present, identify which mode of valve disease is occurring, and the progression of
valve disease. These techniques include x-ray of the chest, transesophogeal
echocardiogram, ultrasound, coronary angiography, and computed tomography (CT)
scans of the heart. Echocardiography can be used to visualize the effective orifice area of
the physical valve. Similarly, ultrasound can be utilized to characterize the severity of
stenosis or regurgitation. Coronary angiography uses an injectable dye which can allow
visualization of blood flow patterns and indicate alterations in the blood flow such as
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shunted flow through a narrowed valve (valve stenosis) or backflow of blood (valve
insufficiency). Chest x-rays as well as CT scans can visualize location of calcification
build up. Figure 1-16 depicts some common non-invasive diagnostic techniques to
evaluate and assess valvular health.

Figure 1-16. Images from non-invasive techniques for determining valvular disease.
(Left) Chest X-ray showing calcified left atrial wall, (Middle) Transesophogeal
echocardiogram shows echo contrast in left atrium, (Right) Computed Tomogram shows
calcification in left atrium [39].
Robust yet efficient assessment of heart valve disease is tantamount to provide the
best healthcare options to the patient. Early detection of valve disease can allow for less
risky preventative measures rather than higher risk intervention techniques. The earlier
healthcare providers can assess the situation, the more informed the decision can be to
proceed forward with a prescribed course of action.

1.4.1

No treatment

If valve disease is caught early enough, life style chances can delay the need of
risky intervention and perhaps even eliminate the prospect of highly risky intervention.
Drugs and other therapeutics may also curb the severity of symptoms. However, there is
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currently no drug therapy that stops or cures degenerative valve disease. There are only
methods to slow down the progression of valve disease without surgical intervention.
1.4.2

Non invasive treatment

Percutaneous intervention is becoming more and more common because it allows
the healthcare provider to implant a heart valve without major surgery. This treatment
method utilizes a balloon valvuloplasty that is similar to angioplasty in occluded
vasculature and the expansion of the balloon reopens the leaflets. This method can also
be used to implant a folded bioprosthetic heart valve (BHV) into the aortic or mitral valve
position without major surgery. Instead of open heart surgery where the patient is put on
bypass, a small incision is made at the femoral artery and a catheter is maneuvered into
the aortic conduit and a compressed, stented BHV valve is ballooned into position much
like an angioplasty. More about transcatheter valves is discussed in section 1.5.4.
With more innovations coming forth with percutaneous valve improvements, the
market is shifting towards percutaneous intervention due to the lower risk associated with
no major surgery needed. However, there are still risks associated with percutaneous
intervention. If patients have hypertension, atheroschlerosis, or have heavy calcification
or plaque build-up within their vasculature, they are not optimal candidates for
percutaneous intervention because the catheter can shear off emboli or the catheter itself
can rupture the vasculature causing hemorrhage.
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1.4.3

Surgical repair

Surgical repair utilizes autologous or xenographic tissue patches to repair holes or
reinforce structurally degraded valve tissue or congenital defects. Surgical repair can also
involve physical removal of calcification [59]. However, often times these are only
bridging treatments that delay the progression of valve disease. Surgical repair of a
damaged native valve does not cure valve disease and inevitably, the patient will need a
heart valve replacement. However, surgical repair can bridge them to a more optimal
time to receive a heart valve replacement.

1.4.4

Heart valve replacement

Once other options are exhausted, healthcare providers must resort to the riskiest
treatment option which is heart valve replacement or valvuloplasty. This treatment option
is most risky because it involves open heart surgery and the patient must be put on
bypass. There are two types of heart valve replacements – (1) bioprosthetic heart valves
(BHVs) and (2) mechanical heart valves (MHVs). Each heart valve replacement option
has its advantages and disadvantages. Below, in Figure 1-17, describes what metrics are
used to determine when it is appropriate to perform surgical intervention. Below in figure
It should be noted that because heart valve replacements have limited longevity,
pediatric patients can undergo what is called a Ross procedure. The Ross procedure
involves taking out the diseased aortic valve and harvesting an autograft from the
patient’s own body, in this case the pulmonary valve, then transplanting the pulmonary
valve into the aortic position. The pulmonary valve is then replaced using a HVR.
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Of all procedures, the Ross procedure requires the most technical skill and is
relatively the riskiest procedure because it involves replacing two valves. However, the
benefits, if successful, greatly benefit the patient in terms of increase in life expectancy.
Because the pulmonary valve is their own, the transplanted valve to the aortic position
grows with the child and does not need any anticoagulant therapy while maintaining
hemodynamics [60].

Figure 1-17. Indications for surgery or intervention for different degenerative valvular
disease modes [42].
Because open heart surgery is a major risk to the patient as well as the
downstream requirements of major surgery, preexisting conditions and age play a
significant role to determining what heart valve replacement is appropriate. Patient
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preference and life style choice also plays an important role in determining what
prosthesis is appropriate for each patient because patient compliance is vital to the
longevity of the replacement valve. Therefore, heart valve replacement selection should
be a split decision that considers the health risks and benefits as well as the lifestyle of
the patient. Figure 1-18 and figure 1-19 are two different decision flow charts used by
healthcare providers to select which heart valve replacement is appropriate on a patient
basis. Sections 1.4.5, 1.4.6, 1.4.7, 1.4.8, and 1.4.9 discuss the value propositions and
drawbacks of each treatment option for total heart valve replacement.
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Figure 1-18.

Heart valve replacement flow chart used by clinicians in Australian

surgical unit [61].
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Figure 1-19. Heart valve replacement flow chart used by clinicians in American surgical
unit [62].

1.4.5

Gross overview of history of heart valve development since 1960s

BHVs are the preferred choice of surgeons because BHVs do not require
anticoagulant therapy and offer more native-like hemodynamics than MHVs [2, 13, 60].
Aldehyde treated BHVs are currently the market gold standard for the main patient
segment currently receiving heart valves – elderly patients aged 65+. Figure 1-20 depicts
a brief history of HVRs and the rise of the many designs starting in the 1960s.
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Figure 1-20. Evolution of prosthetic heart valves [63].

1.4.6

Mechanical heart valves

The core concept behind MHVs is to completely replace mechanical function of
the heart valve with synthetic materials. MHVs usually incorporate a bi-leaflet design
often made from biologically inert materials such as pyrolytic carbon. The major value
proposition in using these materials and design is that (1) the materials are engineered
significantly past the lifespan of a human and (2) the geometry, dynamics, and overall
design of the heart valve provide adequate pulsatile system blood flow to the body.
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MHVs are composed entirely of man-made or synthetic materials. There are
several designs for MHVs however they all comprise of three parts: the (1) sewing ring to
attach

to

the

tissue

(flexible

fabric

made

of

polyethylene

terephalate

or

polytetrafluoroethylene), (2) housing (base for sewing ring attachment and guide for
occluder made out of titanium or other flexible yet strong biocompatible metal alloy), and
(3) occluder (fabricated out of a biologically inert material usually pyrolytic carbon). The
sewing ring serves as an attachment point for surgeons during valvuloplasty and the
housing gives structure to the MHV. The occluder is the moving component of the MHV
allowing pulsatile blood flow through the conduit. Below, figure 1-21 illustrates older
designs (A-D) and designs currently available on market (E-F).

34

Figure 1-21. Mechanical Heart Valves (A) Hufnagel [64], (B) Starr-Edwards [65], (C)
Bjork-Shiley [94], (D) Medtronic-Hall [64], (E) St Jude Bileaflet [66], (F) On-X Life
Technologies (http://www.onxlti.com/).

The first heart valve replacements back in the 1960s were MHVs. These early
MHVs consisted of a ball in cage model similar to Figure 1-21A. Over the years, it was
found that proteins adsorbed to the nylon/silicone polymers used to fabricate these balls
that affected long term functionality. Furthermore, as more materials were being
discovered that were stronger, lighter in weight, and had higher biological inertness, the
materials for the cage changed from methylmethacrylate to metal cages and the ball
changing from basic copolymer blends to advanced materials such as pyrolytic carbon, a
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strong thromboresistant metal that is biologically inert. These ball in cage model MHVs
were common in the early years of heart valve replacements [64].
After many innovations in material improvement used in MHVs, next came
innovations in design. The next big iteration in MHV design was the Bjork-Shiley valve
that ditched the ball in cage design and utilized instead a single, flat tilting disc design in
1969. These valves consisted of a pair of wire retaining struts welded to an orifice, and a
disc tilting to allow for the passage and stoppage of blood flow based on pressure
gradients across the conduit. The housing consisted of stellite [67-69]. The disc was
initially made of delrin however with the emergence of pyrolytic carbon, delrin which
changed shape due to its inherent hygroscopic nature was replaced with the superior
pyrolytic carbon [68, 69]. Changes to valve design also included replacing the flat
surfaces with a convex-concave disc design to allow for better hemodynamic profiles [68,
69]. These design iterations produced a superior performance and led to implantation in
over 100,000 patients [67]. Following this initial success in tilting disc design, other heart
valve manufacturers began to roll out their own lines of tilting disc design. By this time,
over 300,000 MHVs with tilting disc design were implanted [70-72].
The next jump in innovation in MHVs was the development of bileaflet design.
Four revolutionary bileaflet disc valves were developed from 1960-1986: the GottDaggett [73], Lillehei-Kalke [74], St Jude Medical bileaflet, and Carbomedics bileaflet
valves [63, 75]. These discs all contain a ring and pair of discs housed within which
rotate to allow blood flow based on pressure gradients across the valve orifice. Prior to
implantation, benzalkonium chloride treatment sterilized the valve, followed by a heparin
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rinse to reduce thrombus formation . The Lillehei-Kalke was discontinued quickly due to
high thrombogenicity [64, 74]. Both the St Jude Medical and Carbomedics valves are
composed of pyrolytic carbon. The St Jude Medical bileaflet valve remains the most
widely implanted mechanical valve. By 2003 an estimated 800,000 were implanted in the
aortic position alone [76-78]. However, new arrivals onto the market such as On-X Life
Technologies are quickly grabbing market share and demonstrating reductions in major
bleeding events while maintaining optimal function.
Drawbacks of this design are that the any occluder design, although optimized to
reduce irregular flow patterns to mimic native blood flow as much as possible, still forces
blood past a very non-native junction at the strut where the polycarbonate occlude(s) is
attached. This causes irregular shearing patterns in the blood that activate the coagulation
cascade making MHVs highly thrombogenic. It should be noted that MHV
thrombogenicity has no correlation with the material selection – it is the inherent
geometry of the MHV causing irregular shear patterns within the blood that elicits a
coagulation response. Therefore, MHV recipients must be put on anticoagulant therapy
such as warfarin, cumodin, or other blood-thinning anticoagulants for the duration of
implant use. Usually, patient compromise is due to this anticoagulant therapy because
these anticoagulation agents are highly toxic and can lead to other lethal complications.
There is increased risk of major bleeding events associated with MHVs [10].
This design has value proposition in the small patient segment in developed
economies that fall between the ages of 45-55 years of age. This patient demographic is
still very mobile and immune competent. Implanting the alternative, BHVs, in this patient
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segment would be catastrophic as BHVs fail more rapidly in younger patients therefore
surgeons opt for MHVs for their durability and patients’ ability to handle the
anticoagulation therapy.

1.4.7 Bioprosthetic heart valves
The majority of the HVR patient segment receives a BHV. BHVs are fabricated
from chemically treated tissues derived from connective tissue in animals. Two
biologically based materials have been approved for clinical use as xenogenic tissue in
BHVs: whole porcine aortic valves, and bovine pericardium-based valves [79-82]. Figure
1-22 depicts select models of BHVs that are currently available on market. The heart
valve tissue bares all the loads and fatigue cycling of the system therefore biomaterial
engineering is of utmost importance in BHV engineering. Currently, the standard practice
in industry is to chemically tan bovine pericardium or porcine aortic heart valve leaflets
with glutaraldehyde to produce a durable yet viscoelastic material that can deform to
allow for the complex valve leaflet biomechanics for hundreds of millions of cycles.
Tissue antigenicity must be reduced prior to implantation, and can be accomplished
through multiple treatments, but glutaraldehyde is the only one clinically used.
Glutaraldehyde has the benefit of crosslinking collagen to allow for improved durability
long term and devitalizing cells in the tissue to hide immunogenic residues.
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Figure 1-22. Bioprosthetic valves currently available on market. (A) CarpentierEdwardss PERIMOUNT Magnas Pericardial Bioprosthesis (Stented) [8], (B) Edwards
Prima Pluss Stentless Bioprosthesis [8], (C) Edwards Sapien Pericardial Percutaneous
Valve [83], (D) CoreValve Percutaneous Valve [83].

1.4.8

Fixation with glutaraldehyde

Glutaraldehyde (1,5-pentanedialdehyde) is used to crosslink soft connective tissue
derived from porcine aortic valve leaflets (PAVs) or bovine pericardium (BP) to produce
the biomaterial used to fabricate BHVs. Glutaraldehyde is most stable in its bifunctional
five carbon aldehyde but can exist in aqueous solution as a free aldehyde, monohydrate,
dihydrate, hemiacetal, or any polymerized form. Glutaraldehyde crosslinks two free
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amine groups through a Schiff-base reaction and aldol condensation can give rise to
glutaraldehyde monomers to polymerize with each other to create variable chain bonds
between the free amine groups. Because free amine groups are predominantly abundant
in collagen, glutaraldehyde is able to crosslink collagen effectively [84, 85]. Figure 1-23
illustrates glutaraldehyde in its monomeric form and how it creates variable length chains
between collagen molecules.

Figure 1-23. Glutaraldehyde (Left) monomer structure free polymerizes in ring form and
(Right) schematic of reaction with collagen [86].
Further add-on technologies have been stacked on top of glutaraldehyde treated
tissues to improve the durability and biocompatibility however structural degradation still
remains an issue with BHVs. These are further discussed in section 1.5.5.

1.4.9

Bioprosthetic heart valves raw materials

PAV leaflets were first used because they mimicked very closely the native
human aortic valve. PAV leaflets, like our own leaflets, have three layers: (1) the fibrosa,
(2) the spongiosa, and (3) the ventricularis. This three-layer structure is depicted in
Figure 1-24. The fibrosa faces the aortic side of the leaflet and contains highly
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circumferentially aligned type VII collagen to give the leaflet structure and strength to
withstand its high cyclic pressure environment [16, 87, 88]. Facing the opposite side
towards the ventricle, the ventricularis also contains collagen however its key component
is radially aligned elastin. The ventricularis functions in providing elasticity and recoil to
the leaflet [15, 18]. This allows the PAV to create the pressure gradients necessary for
pulsatile circulation of blood after ventricular systole. In the middle of the fibrosa and
ventricularis lies the spongiosa that primarily contains GAGs. This layer is believed to
mechanically function as a shearing medium between the two other layers because the
GAGs form a hydrogel-like layer [27, 89].

Figure 1-24. Histological representation of three layers within PAV ECM. (A) Fibrosa
layer with heavy circumferentially aligned collagen content illustrated in yellow. (B)
Spongiosa layer comprising of GAGs illustrated in blue and collagen. (C) Ventricularis
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layer comprising of collagen and radially aligned elastin illustrated in dark purple and
black fibrous structures [90].
The structure of pericardium is different from the structure of PAV leaflets. The
pericardium contains a smooth inner layer, middle fibrosa layer, and an outer rough layer
[79, 82]. The rough layer contains collagen and elastin which must be trimmed from
desired tissue to present a more uniform surface. This surface is still rough, so it becomes
the inflow surface which allows for washing of the surface to prevent thrombus
formation. Figure 1-25 depicts the microstructure of this surface. The fibrosa contains
collagen, elastin, microvessels, and nerve bundles. BP is essentially a collagen mesh that
has glycosaminoglycans (GAGs) and elastin dispersed throughout the tissue composite.
Though BP contains the same components (collagen, GAGs, and elastin) as PAV leaflets,
BP is in stark contrast to PAV leaflet due to the composition and orientation of these
protein structures. BP is ~95% collagen with very little ground substances (GAGs) and
interdispersed elastin throughout the mesh oriented in various directions that is not
necessarily aligned with the BP. Pericardial based valves allow for optimization of design
for improved hemodynamics, but their vastly different structure imparts inferior
biomechanics for durability [81, 91, 92].
BP as a raw soft connective tissue within it a multitude of orientations varying by
region. BHV manufacturers that utilize BP as the base material for BHV fabrication
select BP based on alignment orientation and thickness specifications set forth within the
protocol of the company. Figure 8 illustrates the range of mesh oriented collagen fibers
that are within BP. Previous literature has established that these tissues are highly
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complex nonlinear materials that have preferred orientations [93, 94] and the
biomechanical properties are dependent on the initial fixation pressure [95] as well as
how long and what type of mechanical load/deformation is placed upon the material post
fabrication [17, 93, 96, 97]

Figure 1-25. Scanning electron microscopy images of collagen in bovine pericardium.
BP from a manufacturing standpoint is much easier to handle and is most likely
the largest driving factor in it becoming the preferred design from suppliers because it
drives down overhead costs and increases operational margin. Large sheets can be preselected according to desired thickness and mesh fiber orientation then treated with
relatively lower volumes of glutaraldehyde solution than the amount that would be
required from PAV leaflets. This process can be highly automated giving BP users a
distinct cost advantage at large production volumes. These sheets can then be cut into
strips in a proprietary geometry such that the strips can be wrapped and stitched around
stents to form the tri-valve design. It should be noted that the assembly process of all
BHVs (including PAV derived BHVs) are still done by hand and thus is heavily protected
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by not only a portfolio of methods and design patents but technical know-how in these
companies’ human capital.
BHVs fabricated from PAV leaflets are less congruent with optimal
manufacturing processes because selection requires many animals (specifically grown for
heart valve materials) and is not easily automated. Only the non-coronary leaflets (one
each valve) are considered as candidates for heart valve fabrication. Only the best noncoronary leaflet from a group of animals is used in the fabrication of the final BHV.
Therefore, it takes multitudes of animals to produce one PAV derived BHV. These
leaflets, all different in geometry, must also be individually cut and stitched together onto
the stent to form the tri-leaflet structure. These BHVs are then stuffed and cross linked in
glutaraldehyde under a pressure head.
These deviations in manufacturing technique could be producing very different
products long-term, especially using a zero-set treatment technique with BP versus a pretension treatment technique that puts an inherent tension in the PAV leaflets [95]. Longterm data isolating these two variables in large patient groups is not available. However,
BP and PAV leaflets are fundamentally the same in one respect – they are both made of
the same extracellular matrix (ECM) components. The varying amounts of those ECM
components and structural organization of these components are what gives rise to
differing tissue composites which will manifest in different biomechanical responses.
Though composed of the same ECM components, BP is a material in stark contrast to
PAV leaflets in the variation in ECM components and how these ECM components are
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organized. This material design elicits completely different material properties even
before downstream processes such as fixation and valve design.
Shortcomings of BHVs are in that they calcify and structurally degrade [3, 95-99].
Additionally, glutaraldehyde crosslinking has previously been shown that depletion of
ECM proteins can cause deviations in biomechanics and could contribute to structural
degradation [15, 18, 27, 35, 55]. Despite these shortcomings, it continues to be standard
industry practice to prioritize collagen fixation and removing potential nucleation sites
for calcification through the use of glutaraldehyde.

1.4.10 Transcatheter heart valves
Percutaneous intervention hinges on innovations in transcatheter heart valves.
Transcatheter heart valves can be implanted minimally invasively via catheterization.
These valves are comprised of a BHV mounted on a collapsible stent that is loaded onto a
catheter. An incision is made typically in the femoral artery and the catheter and stent is
inserted and delivered to the desired heart valve position. The stent is then ballooned out
at the desired region and the valve hooks into the aortic root and pushes the existing
leaflets aside. The catheter is then retracted and the implant is monitored. Other
procedures to implant are also via apical delivery of transcatheter valves in which an
incision is made in the left ribs and the catheter is delivered through the heart wall of the
left ventricle into the desired position.
The advantage of transcatheter valves is they are minimally invasive and do not
require major open heart surgery. The hemodynamics and functionality of a BHV can be
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closely mimicked by a transcatheter valve however there is still no long term data
regarding the efficacy and safety of these implants because the technology is fairly new.
Drawbacks of transcatheter valves is that they are more structurally instable and
misalignment is often an issue because the surgeon must deliver it using a catheter in a
closed space using angiography as a visual guide compared to open heart surgery in
which the surgeon is using their hands and using direct visual cues of anatomical
landmarks. There is also debate currently between surgeons as to whether femoral artery
delivery or apical delivery is best. It comes down to surgeon preference in what they are
comfortable with as well as the state of the patient. Apical delivery requires entry through
the heart wall which may be risky and also requires resuturing of the heart wall and
recovery of cardiac muscle while femoral delivery does not. However, femoral delivery is
highly risky in hypertensive patients with calcification or plaque build-up in their arteries
and has a much longer distance of travel to delivery than apical delivery.
The transcatheter valve is currently where most of the commercial innovation is
occurring within the heart valve replacement space in terms of finding ways to better
fabricate and fold the biomaterial such that it does not exhibit crimps and to yield smaller
diameter stents to lower risk of the stent coming in contact with vasculature walls during
delivery.

1.5

Shortcomings of Replacement Heart Valves

“At the same time, market-driven preferences for either bovine pericardial or
porcine aortic valves cultivated a pseudo sense of progress amongst surgeons while in
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fact they merely reflected the circumstances of the time rather than scientific insight.
While in previous eras clinical failures due to design flaws affected the surgeon’s
preferences for bovine or porcine products, prion and virus concerns as well as tissue
availabilities and production advantages determine today’s marketing thrusts towards
‘bovine’ or ‘porcine’ valves” [3].
BHVs are susceptible to degradation and other biological insults that the MHV
materials are engineered to be much more resistant to. For this reason, from a strictly
mechanical standpoint, MHVs are much more structurally robust than BHVs. However,
again, because of the anticoagulation therapy, there is actually no significant difference
between the two implants when using the metrics of implant life in patients aged 50-69
[100]. Again, as illustrated in figure 1-26 and figure 1-27, it becomes a lifestyle choice
when patients are outside of the bell curve demographic of 60-75 years of age or in
patients below the age of 65 years of age [101]. Also, there seems to be cultural
preferences in implantation. In some American surgical units, up to 80% of HVRs are
BHVs [16] while in some other developed countries such as Australia, there is a slight
preference in MHVs in the 50-70 year old age demographic [101]. However, with
emerging technology in transcatheter/percutaneous valves, there may be disruption to the
market preferences in how surgeons choose to treat heart valve disease.
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Figure 1-26. Kaplan-Meier survival curves based on reconstructed individual study data.
Aggregated survival curves for bioprosthetic valve (blue lines) compared with
mechanical valve (red lines) after aortic valve replacement in patients aged (A) 50 to 70
years; (B) 60 to 70 years; and (C) less than 65 years. (CI = confidence interval; HR =
hazard ratio.) [101]

Figure 1-27. Rates of complications and adverse events of HVR requiring reoperation or
intervention [100].
The tradeoff between BHVs and MHVs are in their failure rates. Both BHV and
MHV failure rates start to occur 10-15 years after implantation [10, 100]; however, BHV
failure rates occur earlier younger patients sometimes as soon as 5-7 years after
implantation [1, 7, 8]. The two main modes of failure in BHVs are calcification and/or
structural degeneration leading to tearing [1, 3]. These two failure modes are not
mutually exclusive as both have occurred together as well as independently [97].
BHVs start to experience failure modes around 10-15 years after implantation [1,
5]. BHVs primarily fail due to (1) infective endocarditis, (2) thromboembolism, (3) nondysfunctional failure, and (4) structural degradation [1]. Structural degradation are the
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main failure modes from a biomaterials perspective long term. These failure modes can
occur independently or concurrently and can be synergistic. The subsequent sections will
focus on failure modes of BHVs.
1.5.1

Infective endocarditis

Infective endocarditis progression is similar to that of native valve infective
endocarditis save the manner in which the infection originates. In BHV implants, the
most likely culprit is during the initial implantation surgery of the BHV. Therefore,
infective endocarditis incidence rates are more associated with surgeon skill and sterility
of the BHV implanted [48, 49, 52, 77, 102-106]. Infective endocarditis can be treated
with antibiotics pending early detection. If left untreated, infective endocarditis can lead
to detachment of the implant from the suture line (dehiscence). Emerging technology and
research in decreasing rates of infective endocarditis has focused on producing antibiotic
suture rings that decrease the chance of bacterial infection. Figure 1-28 depicts a valve
explanted due to infective endocarditis.
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Figure 1-28. Porcine BHV from mitral position, implanted for 7 years. Prosthesis shows
thickening of cusps and white vegetations from infection [39].
1.5.2

Thromboembolism in BHVs

Though BHVs experience less major bleeding events than MHVs, there is still
incidence of major bleeding events associated with BHVs. Thromboembolism risk is still
high for three months post-operation therefore the patient is placed on anticoagulants
during this time. However, these patients do not have to take life long anticoagulants like
their MHV counterparts. Incidence of major bleeding events excluding other covariates
start to flat line out past 12 years at 7% and is significantly less than the reported
incidence of bleeding events associated with MHVs [10].
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1.5.3

Non-dysfunctional and infection failure

Non-dysfunctional failure of BHVs are associated with external factors that do
not deal directly with the inherent prosthetic itself. These include pannus overgrowth,
hemolysis, and paravalvular leakage. Pannus overgrowth is the growth of fibrous tissue
extending from the suture ring that slowly encroaches on the leaflets. Eventually, this
fibrous tissue starts to affect leaflet range of motion and if left untreated can completely
render the leaflet immobile. It essentially creates a stenotic valve. The effects of pannus
overgrowth is shown in figure 1-29. Hemolysis occurs when red blood cells experience
increased shearing that causes the red blood cells to rupture. This can activate the blood
coagulation cascade and initiate thrombus formation. With better hemodynamics in
BHVs, this incidence is low however hemolysis is the reason why MHVs require lifelong
anticoagulation treatment because there is high turbulent flow initially coming out of the
valve. Paravalvular leakage occurs when the implant becomes detached from the suture
line and blood is able to circumvent the prosthesis. This is usually caused by infective
endocarditis and effectively creates an insufficient valve because there is backflow of
blood into the ventricle.
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Figure 1-29. Torn leaflet in BHV in aortic position and extensive pannus formation
covering portions of the leaflets [67].

1.5.4

Structural degradation

Of the failure modes, structural degradation is the predominant mode of failure in
BHVs. Structural degradation can occur with or without calcification. BHV calcification
manifests symptomatically much like native heart valve calcification in that calcification
nodules form and inhibit leaflet function thereby creating a stenotic valve. BHV
structural degradation without the presence of calcification is a result of cyclic
mechanical fatigue as well as loss of ECM proteins left unstabilized by glutaraldehyde.
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These separate processes of structural degradation are not mutually exclusive as they can
occur together or independently [97] as depicted in figure 1-30.

Figure 1-30. Model for structural dysfunction in bioprosthetic heart valves. Two
pathways are shown, one induced by stress, resulting in structural degeneration and valve
failure. The other is affected by implant and host factors, results in cuspal calcification
and valve failure. Implant and host factors induce collagen-oriented deposits, seen in the
ultrastructure, and predominate at flexion points and commissures. The pathways are not
independent, however, since structural degeneration predisposes cusps to calcification
[13].

1.5.4.1 Structural degradation through calcification
Major barriers to addressing calcification in BHVs are in a limited understanding
of the mechanisms initiating the onset of calcification. Though it has been established
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historically in literature that calcification is a passive process of calcification beginning
from nucleation sites at cellular debris left in BHV materials [98, 107-110], however it is
currently unknown as to how and why these nucleation sites manifest and how they
aggregate into stenosis inducing calcification nodules. Figure 1-31 depicts the
predominating hypothesis in how calcification in BHVs occur.

Figure 1-31. Overarching hypothesis within the literature pertaining to mechanisms
underpinning calcification for BHV failure [1].
The five overarching processes that have demonstrated the capacity to play a role
in calcification are (1) cellular debris, particularly the phospholipid content that provides
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a high affinity binding site for minerals such as calcium, provide the substrate for
nucleation site formation [1], (2) damaged ECM (both elastin and collagen) providing
high affinity substrates for mineralization occur [107, 108, 111-116], (3) it has previously
been shown that glutaraldehyde itself, specifically free floating aldehydes not bound, are
highly toxic and may predispose tissue to calcification [109, 110, 117, 118], (4) oxidative
stress [119], and (5) an active cellular response that maybe contributing to calcification
[120]. Because there are multiple driving factors to calcification, it has been difficult to
discern the exact mechanism in how calcification progresses giving rise to multiple
intertwined hypotheses in causes for calcification.
The main mechanism behind believing that devitalized cellular components may
be the initiation sites of calcification is that viable cells have sodium-ion pumps to
regulate calcium influx. However, once these cells are devitalized, the influx of calcium
cannot be flushed out because these sodium-ion pumps are no longer metabolically active
[98, 121-124]. This accumulation of calcium binds to the intracellular phosphorus content
thereby resulting in the nucleation sites that can initiate calcification nodule formation
[98].
However, there have been alternative crosslinking chemistries that do not calcify
despite cellular debris being left in the implant suggesting that there are multiple
pathways of calcification. Additionally, there have been studies showing that calcification
can occur in collagen sponges [109]. These tissues are devoid of any devitalized cells and
calcification nodules were still found to have developed as depicted in figure 1-32.
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Figure 1-32. Histological analysis of calcification nodules in collagenous sponges
implanted into nude mice. Importance of this study shows that in the absence of immune
system as well as cellular debris, glutaraldehyde crosslinked collagen sponges still calcify
further blurring the underlying driving factors of calcification [109].
Degraded ECM proteins or loss of ECM proteins have been heavily correlated
with calcification. Elastin calcification is believed to occur due to pockets of high affinity
binding sites for calcium once protective layers of glycoproteins and microfibrils are
degraded away from the core elastin fiber during tissue fabrication or MMP activity [56,
111, 122, 125-130]. It has also been previously demonstrated that GAG loss in tissues
resulted in in vivo calcification of samples however samples with GAGs stabilized and
retained exhibited significantly less calcification [145,157,161,166] [115, 131-133].
Furthermore, it has been postulated that GAGs may inhibit calcium build up through
steric hindrance [125]. Aldehyde crosslinked collagen has also been previously shown to
form nucleation sites and calcification nodules [107-110, 116].
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Most recently, ECM destruction has also been linked to the host cellular response
able to physically degrade ECM components such as collagen seen in explanted valves
[134, 135] and oxidative stress able to weaken glutaraldehyde bonds to destabilize
collagen in BHV ECMs [119]. Because it has been established that degraded ECM
components such as collagen and elastin have the propensity to calcify, these may also be
driving factors in BHV calcification.
These data suggest that there are multiple underlying driving factors in
calcification of BHVs and it is most likely the summation and synergy of these processes
working in parallel that produce calcification in BHVs.

1.5.4.2 Structural degradation through mechanical wear and ECM loss
Previous literature shows that loss in other ECM proteins can adversely affect the
mechanical behavior and material properties of BHV materials. In addition to ECM
degradation providing calcification sites as discussed in the previous section, the
mechanical contribution of those ECM proteins are also lost. Just looking at elastin loss,
major deviations in mechanical behavior within the leaflet are lost [15, 18, 35, 81]. Figure
1-33 illustrates the drastic deviations in mechanical behavior due to loss in elastin.
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Figure 1-33. Biomechanics testing showing the alteration in mechanical behavior in
elastin-digested tissues [15].
Though GAGs comprise a small part of the ECM, they play a pivotal role in
leaflet mechanics. It has been previously reported that they play a role in low force
tension [27] and in tissue buckling [28, 132]. The digestion of GAGs via GAGases
produced disadvantageous biomechanical properties as seen in figure 1-34.
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Figure 1-34. Alterations in mechanical behavior in GAG and GAG depleted tissues.
(Top) Reduced hysteresis effects suggesting that leaflets “flutter” and have lost bending
stiffness in GAG depleted tissues. [27]. (Bottom) GAG depleted tissues on the left
buckled more easily than tissues with GAG stabilized tissues [28].
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Furthermore, current treatment methods with glutaraldehyde show the structural
degradation implications of using reversible chemistry in a device that requires high
cyclic fatigue resistance [93, 94]. Figure 1-35 depicts fatigued collagen treated PAVs
exhibit permanent deformations (also called permanent set), deviations in biomechanical
behavior, as well as fiber orientation disruption visible macroscopic deformations.
Depicted in Figure 1-36, just by the naked eye, physical sagging of the inside of the heart
valve as well as stress shunting around the aortic wall can be seen [96]. Accompanying
the macroscopic to microscopic structural degradation, individual collagen fibers at the
protein level exhibits degradation [29, 93]. Figure 1-37 depicts FT-IR spectroscopy
results of fatigued samples as compared to unfatigued samples show a shift in peaks in
the amide regions. The marked amide regions are indicative of the collagen triple helix
structure in which one amide group is facing inward and two facing out. With the
disruption of collagen and “unraveling” of the triple helix, the amide group usually facing
inward is now exposed to solution and shifts the peaks of the spectroscopy to a slightly
altered but detectable wavelength. Therefore, it can be concluded that simply fatiguing
tissues fixed with reversible chemistries such as aldehydes can result in deviations at the
biochemical, microscopic, macroscopic, and gross anatomy level.
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Figure 1-35. Alterations in mechanical behavior in cycled PAVs crosslinked with
glutaraldehyde. (Top) Permanent geometric deformation relative to nominal geometry
imparted by cyclic fatigue testing. (Bottom left) Fatigued samples show a shift in
biomechanical behavior. (Bottom right) Fatigued samples show misaligned collagen fiber
orientation relative to normal cusps when damaged either through in vivo failure or in
vitro accelerated fatigue testing [93].
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Figure 1-36. MRI imaging of macroscopic geometric deformations in fatigued PAVs. (a)
Normal, unfatigued noncoronary cusp. (b) Fatigued noncoronary cusp with visual signs
of sagging. (c) and (d) Fatigued coronary cusps showing sagging [96].
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Figure 1-37. FT-IR spectroscopy investigating the integrity of the collagen triple helix of
a patch of glutaraldehyde treated PAV. Note the amide shifts between the cycled and
control samples in the 1500-1600 wave number spectrum [93].

1.5.4.3 Structural degradation through host cellular response
Throughout the literature, it is unclear how the host cellular response plays into
the calcification response and how it affects the biomaterial in general. Figure 1-38
depicts activated macrophages, phagocytic cells, as well as activated T-cells which have
all been found in failed BHVs explanted from compromised patients [117, 118]. TEM
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images showing collagen fragments in phagocytic vesicles of phagocytes from failed
BHV explants have been reported suggesting an active cellular response in degeneration
of BHVs [136]. However, these studies do not clearly show what triggers these cells into
the hostile activity towards the implant or the pathway progressions these cells are taking
to produce such behavior, though, they do clearly show that phagocytic cells actively
participate in fragmentation of ECM proteins [135, 136]. These could potentially be the
sites necessary for calcification nodule formation. There are data that suggest that the
immunogenicity of the biomaterial itself may be enough to elicit such a response [135]
however even collagen sponges implanted subcutaneously have elicited heavy foreign
body giant cell activity, phagocytic activity, and calcification [109]. Furthermore,
collagen sponges implanted in nude mice (immune cell deficient mice) still presented
with calcification and host cellular infiltration [137].
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Figure 1-38. Histological analysis of explanted valves. (Top) Large animal study sheep
valves. (Bottom) Failed human valves [135, 138, 139].
The literature does not come to a cohesive consensus on the role of the host
cellular response in regards to structural degradation. Though it is accepted that
mechanical fatigue can produce many deviations in biomechanics including flexural
compliance [29], permanent geometric deformation and loss of extensibility [94, 96], and
large disruptions in fiber orientation [93, 95, 99, 140], others have also shown that the
host cellular response is capable of fragmenting ECM components [109, 135, 138, 139]

67

which could potentially further result in more structural degradation. Furthermore, it has
been shown that oxidative stress can damage and weaken glutaraldehyde bonds [119].
Previous research has indicated that glutaraldehyde crosslinking itself may
increase propensity of tissue calcification [109, 110]. Schiff-base crosslinking [85, 141] is
shown to be reversible and susceptible to hydrolysis [85, 142]. Though the reaction can
be made more irreversible by using reducing agents such as sodium tetraborate [143];
such treatments are not used for clinical BHVs. Inability of GLUT crosslinking to stop
degradation of the integrity of the collagen triple helix during cyclic fatigue loading was
shown by shifts in amine peaks in FT-IR experiments [29]. Same studies also showed
that in vitro cyclic fatigue casues change in bending stiffness GLUT treated PAVs
indicating a degradation of the ECM structure [29]. Glutaraldehyde only actively
crosslinks collagen and leaves other key ECM components such as GAGs and elastin
unstabilized in the overall tissue composite [141]. Therefore, these major ECM
components are lost from the tissue due to enzymatic degradation [28, 34, 89, 144]. Slow
depletion of these ECM components compounded with constant cyclic loading may lead
to microtears after valve implantation. This early degeneration may then lead to
calcification nodule development and/or visible tears within a few years. Figure 15
depicts loss or damage of elastin can serve as high affinity calcification sites and it has
also been previously demonstrated that depletion of elastin within soft connective tissues
such as PAVs produces severely deviated biomecahincal properties. Figure 16 depicts
GAGs in BHVs are strongly connected with fiber-fiber and fiber-matrix interactions at
low force levels and that they may be important in providing a damping mechanism to
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reduce leaflet flutter when the leaflet is not under high tensile stress [27]. Thus, the
degradation of the essential ECM components leads to the compromised mechanical
function of the leaflet and this could be a major contributor to degenerative tears of
BHVs.
1.5.5

Alternative fixation techniques for bioprosthetic heart valve fabrication

To date, there are no other chemistries used other than aldehyde chemistry used to
fabricate BHVs for commercial use. Medtronic and Edwards Lifesciences BHVs both use
glutaraldehyde [145, 146] and St. Jude Medical BHVs utilize formaldehyde [147]. The
top three leading companies with BHVs on market are summarized in Table 2 in terms of
fundamental biomaterial fabrication.

Table 1. Comparison of fabrication techniques in various BHV biomaterials currently on
market.
Company

Base biomaterial

Crosslinker

Anti-calcification
Treatment

Edwards

BP

Glutaraldehyde ThermaFix™

PAV

Glutaraldehyde AOA™

Lifesciences
Medtronic

(alpha

oleic

acid) + Physiological
Fixation™
St. Jude Medical

BP

Formaldehdye
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Linx™ AC

Additional technologies that have been tried in an attempt in decreasing structural
degradation processes include ethanol preincubation [112, 129, 132, 143, 148-151],
diamine crosslinking [84, 85, 139, 152, 153], hydrogel incorporation [154], among others
have demonstrated good efficacy in in vitro and in vivo models however have not made it
out of academia into clinical trials. Ethanol and surfactant treatment of the tissue are used
in an effort to deplete the biomaterial of devitalized cellular debris that is calcification
prone however it has only demonstrated the ability to delay calcification, not prevent it.
Diamine crosslinking has previously been demonstrated to produce a viably more durable
valve however involves the use of sodium hydrotetraborate, a highly toxic chemical.
Hydrogel incorporation has only been demonstrated at a proof of concept level at the
bench top level.
However, there are a multitude of approaches to create entirely new materials in
academia that are under peer reviewed research that seek to replace glutraldehyde, not
simply add onto it. Figure 1-39 depicts many the of different techniques used to stabilize
collagen in soft connective tissue applications such as BHV fabrication. These fixation
chemistries include epoxies, acyl azides [135], polyethylene glycol [136,137], quercetin
[138], carbodiimide [28,139-144], periodate [142,145], triglycidylamine [135], and dye
mediated photo oxidation [134,146]. Each have had their own successes and were mainly
developed to decrease calcification with carodiimide and epoxy-based chemistries
making it to clinical trials however with limited success.
Despite the plethora of methods to make a new material, all revolve around the
same concepts. These concepts center around using a crosslinking chemistry that is much
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more irreversible than aldehyde chemistry and have previously been demonstrated to be
resistant to calcification, mechanical wear, and host cellular degradation. The rationale
behind using more irreversible chemistries is that the bonds crosslinking the ECM
proteins are more stable. This is especially important when crosslinking collagen as
collagen is the ECM protein that provides all the load bearing strength required of BHVs.
A more stable bond should lead to a higher level of collagen stability and resistance to
degradation that should lead to the resistance of permanent biomechanical alterations
within the tissue composite. From this process, the BHV can be designed to minimize
stress concentrations and resist stress shunting and thus microtear formation. A lower
incidence of microtear formation should result in less tearing and catastrophic failure of
BHVs due to structural degradation.

71

72

Figure 1-39. Different stabilizing and crosslinking agents demonstrated to adequately
crosslink collagen to produce biomaterials and scaffolds [141].
The art of crosslinking and the underlying fundamentals of finding the optimal
chemistry for BHV fabrication lies in the crosslinking technique’s ability to produce a
structurally very durable, tough biomaterial but still retain compliancy even at high
volumes of cyclic mechanical deformation. In other words, the crosslinking scheme must
produce very stable bonds but not produce such a rigid tissue composite that the BHV
cannot function as a visco-elastic material. It should also aim to preserve other ECM
proteins inherent to the raw ECM to help retain more advantageous biomechanics and
reduce risk of structural degeneration through degraded protein content.

1.5.6

Previous strategies to prevent GAG loss

It has previously been discussed that BHV biomaterials that could not retain
GAGs promoted calcification and those that stabilized GAGs and prevented loss showed
a significant reduction in calcification [89, 132, 155]. Additionally, these tissues did not
have a tendency to buckle when compared to GAGase treated samples [28, 132].
Furthermore, it seems that GAGs may play an advantageous role biomechanically [27,
29, 122, 156, 157]. Therefore, it would be in the best interest for the next iteration of
tissue based BHV biomaterials to find a method in which to retain GAGs.
The literature has shown that GAGs are lost during the preparation period of the
biomaterial through endogenous enzyme activity [89, 131, 144, 158] as well as
mechanical cycling during the functional implant life of the BHV [29]. Therefore,
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strategies aimed to retain GAGs should mitigate these two processes – prevent enzymatic
degradation of GAGs as well as GAG leeching during high cyclic fatigue. The GAGs
must be incorporated into the crosslinking scheme much like collagen to accomplish this.
Previous attempts at stabilizing GAGs have been through the use of compounds
that can link chemical substrates readily available on GAGs, specifically hyaluronon –
the GAG backbone, to the same substrates used in the base crosslinking chemistry. This
resulted in a search for a compound that could bind modularly to GAG substrates and
provide substrate for aldehyde chemistry to bind to.
Sodium metaperiodate utilized the periodate ion to activate diols within
hyaluronic acid to aldehyde groups thereby allowing reactions with lysyl amine groups
and other molecules within the tissue o reaction [20,142,145]. This created an
interconnected meshed network of collagen as well as GAGs crosslinked by
glutaraldehyde. This method was able to retain GAGs through 21 days n vivo small
animal implantation as well as demonstrate the ability to produce reduction in
calcification compared to glutraldehyde only treated groups [131].
A second technique attempted in stabilizing GAGs also attempted to replace
glutaraldehyde as a crosslinking agent because of the cytotoxic properties of free
aldehyde residues as well as the reversibility of the aldehyde bonds. The investigators
wanted to create a more stable network with irreversible chemistry to create an
interconnected mesh that stabilized collagen as well as GAGs to a higher degree. The
resulting technique was the use of neomycin in combination with carbodiimide
crosslinking chemistry [159].
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Girardot et al. patented a novel process using carbodiimide cross linking
chemistry with the intent of down regulating calcification [13]. Carbodiimide makes use
of EDC (1-ethyl-3-3-dimethylaminopropyl carbodiimide) and NHS (Nhydroxysuccinimide) to create crosslinks [28,141-144]. EDC activates the substrate on
compounds and NHS is an intermediate stabilizer thus NHS is used to speed up the
chemical reaction. This reaction is depicted in figure 1-40. Carobdiimide utilizes
carboxyl and free amine groups to form a bond however carbodiimide does not leave
behind a variable length chain as in the case of glutaraldehyde and thus said to be “zero
length” – in other words, it is a direct link between the amine and carboxyl group with no
functional groups in the middle of the crosslink (as seen with aldehyde based
crosslinking) [6, 13 – 15].

Figure 1-40. Reaction of carbodiimide and collagen, activated by NHS [167].
Carbodiimide, like glutaraldehyde, cannot stabilize GAGs within the ECM alone.
Therefore, neomycin, a hyaluronidase inhibitor with 5 free amine groups, was
incorporated into the crosslinking method. Neomycin was first used with glutaraldehyde
to demonstrate a protective effect in preventing GAG loss [144, 157, 160] however with
limited success because glutaraldehyde was still being used. When used with
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carbodiimide, it formed a comparable stable interconnected mesh that retained GAGs,
collagen, and resisted calcification [159].

Figure 1-41. Chemical structure of neomycin trisulfate (www.drugs.com).
This rationale behind using this particular chemistry was that it sought to mitigate
the two methods in which GAGs were depleted from the tissue. Neomycin, being a
hyaluronidase inhibitor, actively prevented protease digestion of the hyaluronon
backbone during material preparation and the use of irreversible, zero-length
carbodiimide chemistry provided much more stable bonds that may be able to produce a
more durable material that can survive more cyclic loading. It should be noted that
neomycin may be acting as a network extender to create multinode crosslinking
throughout the tissue.

76

1.5.7

Previous strategies to stabilize elastin

It has been previously demonstrated that active proteases can degrade elastin.
Some of these enzymes are to pancreatic elastase, neutrophil elastase, and matrix
metalloproteinases (MMP-2, MMP-9, and MMP-12) [39,44-46,168-172] [32, 33, 114,
127, 161-165]. These enzymes primarily target the hydrophobic regions of elastin and
these fragments of degraded elastin not only have no mechanical function but begin to
elicit a cellular response such as activating immunological cells, and activating smooth
muscle cells to a proliferative phenotype [173-178] [128, 130, 166-169]. This can cause
further host cellular response to the BHV to degrade more of the biomaterial as well as
cause other complications that can accelerate BHV failure.
Because of the drawbacks in terms of mechanical function, biocompatibility, and
implications in calcification, attempts were made to develop crosslinking methods to
prevent the degradation of elastin.
Searching through the literature, compounds have been previously used to
stabilize elastin in other applications such as pure elastin and the aortic wall. These
compounds are plant polyphenol derivatives called tannins. Tannins include tannic acid
and pentagalloyl glucose (PGG) and have both been demonstrated to stabilize pure elastin
and the aortic wall [126,179-182] [18, 34, 113, 170]. Tannins possess a central glucose
molecule, a chain of gallic acid residues containing a high amount of branched phenolic
hydroxyl groups. Tannic acid was the first candidate for use in stabilizing elastin and was
originally used in histology as a fixative for certain microscopy techniques. However,
there were toxicity concerns revolving around tannic acid thus a smaller tannin derivative
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with only one hydrolysable gallic acid group per chain was selected in an attempt to
develop a better stabilization method for elastin. This compound was PGG. The chemical
structure of tannic acid and PGG are compared in figure 1-42.

Figure 1-42. Chemical structure of tannic acid and pentagalloyl glucose. Tannic acid has
two gallic acid molecules bound by ester bonds to each glucose hydroxyl residue. PGG
is highlighted by the shaded circle and only has one gallic acid molecule at each glucose
hydroxyl residue, thus reducing the number of hydrolysable ester bonds [113].
Tannic acid and PGG are able to nest themselves into proline rich hydrophobic
regions within elastin and collagen to form a network of hydrogen bonds between
multiple surrounding proteins as depicted in figure 1-43. Studies have shown that these
bonds are partially reversible in PGG combined with glutraldehyde treated tissues but are
still more effective than glutaraldehyde alone bonding. Furthermore, glutaraldehyde
treatment alone does not protect elastin from degradation however PGG treated tissues
resist degradation of porcine pancreatic elastase as well as in vivo degradation in small

78

animal studies [155]. Furthermore, it has been previously been shown that concentrations
of PGG used to stabilize aortic walls were not cytotoxic to rat fibroblasts [113, 170].

Figure 1-43. Hypothetical interactions between tannic acid and elastin, comprised of (1)
hydrophilic crosslinks, (2) hydrophobic domains, (3) natural desmosine crosslinks, (4)
tannic acid core incorporated into hydrophobic areas, and (5) hydrogen bonds between
elastin and tannin hydroxyl residues [170].
Additionally, it has been shown that PGG in combination with glutaraldehyde can
stabilize elastin in PAV leaflets and creates a calcification resistant material [155]. This
PGG is also retained in long term storage [155].

1.5.8

Additives for better ECM stabilization in bioprosthetic heart valve fabrication

Additives to a base crosslinking chemistry that stabilizes the main load bearing
components in the BHV ECM can be used to produce a more robust, multi-step
crosslinking technique that protects all ECM components. Previous work in the
Vyavahare lab has demonstrated that neomycin (NEO) in conjunction with a cross
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linking scheme capable of linking amine groups to carboxyl groups (GLUT or Nhydrosuccimide and EDC) stabilizes GAGs [16]. Furthermore, a tannic acid derivative,
pentagalloylglucose (PGG), has been shown to stabilize elastin [17]. When used in
conjunction with a cross linker such as NHS/EDC, PGG can potentially also polymerize.
Both the PGG treatment as well as NHS/EDC treatment, but not independently, has been
shown to significantly down regulate calcification in subcutaneous implants in rats [159].

1.5.9

Developing a more durable biomaterial for an underserved patient segment

The cardiovascular medical device and therapeutics space as an aggregate market is
valued at $92BIL with a 7% CAGR across the industry [171]. Heart valve replacements
represent a $1.25BIL segment of this market with over 300,000 heart valve replacements
per year globally. However, in emerging markets such as the Chinese, Brazilian, and
Indian healthcare markets, the cardiovascular space is experiencing upwards of 10-15%
CAGR annually. With 85% of current healthcare service providers concentrated in
developed economies (only 11% of the human population resides in these regions), the
cardiovascular market (including the heart valve replacement market) is poised to
continue large growth in the next 50 years given suppliers of the cardiovascular space can
meet patient needs in these countries. Market growth will concentrate on penetrating
emerging economies with patient segments that have not yet experienced widespread
healthcare services in the cardiovascular space but also possess the infrastructure needed
to offer these services and to upkeep standard of care [2-4].

80

The current gold standard in the current heart valve market operating primarily in
the developed economy space may not be able to meet all the clinical needs of the new
growth sector in emerging economies. The caveat to catering to this new market segment
centered in emerging economies and often resource lean regions is that this new market
segment will serve a different patient segment or demographic. This means that there will
be different clinical needs that will define different design criteria that will affect current
paradigms in heart valve design [3, 4].
The major difference between developed economy and emerging economy patient
segments in the cardiovascular market is seen if the market is segmented first by
geographic location then by age. Cardiovascular disease, especially in the heart valve
market, is on the rise in developed countries primarily due to chronic conditions causing
health complications later in life. The average age for a heart valve recipient is over 55
years old with the median being ~65 years old. Note from Figure 1-44 that the
distribution of patients when segmented by age in the current market primarily operating
in developed nations is very narrow, stark, and heavily skewed towards patients 60-69
years of age. Congenital conditions and infectious disease that damage the heart
necessitating a heart valve transplant (such as rheumatic fever) in the current
demographic the heart valve market serves now is relatively low compared to that of the
new patient segments in emerging economies.
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Figure 1-44. Contrasting patient demographics in developed countries (red line) and
developing countries (blue line) [3].

Figure 1-45. Global map color coding countries according to size of economy and
quality of life. It should be noted that 85% of the healthcare market is generated in
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advanced economies labeled in blue. Only 11% of the human population resides in these
regions leaving the majority of humanity to have little access to healthcare services and
products.
The new patient demographic segmented by age observes a stark difference in
patient distribution. The distribution curve is much flatter encompassing a larger range of
ages receiving heart valve replacements with the median age receiving a heart valve
transplant at 45 years of age and the most common age receiving a heart valve
replacement at ~35 years of age. It should also be noted that a large bulk of the aggregate
heart valve replacement recipients were younger than 35 years of age. This wide age
range is due to inherent differences in the underlying conditions necessitating a heart
valve replacement. In these often resource lean regions, congenital conditions and disease
states often cause heart valve disease and are no longer near negligible drivers of heart
valve replacements. This is contrary to long term chronic conditions mainly due to
genetics or lifestyle leading to slow but progressive degenerative conditions as seen in
developed regions. This key difference in causation of needing heart valve replacements
will inherently drive a different set of demand criteria from a user and healthcare provider
standpoint that heart valve replacement suppliers must address in their heart valve design.
Because of there are drastically different clinical needs between the current
developed world market and emerging economy market, there must be changes in heart
valve design to fully capture market share and effectively serve the new patient
demographic in emerging economies. Because the market’s current patient segment
served is predominantly elderly, current heart valve durability and implant lifespan is
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engineered only to 10-15 years before failure rates start to occur [1, 7]. Strictly based on
patient age demographic, the current market gold standards for heart valve replacements
will not serve the emerging economy heart valve replacement market because the average
recipient age is ~30 years or half the age of developed economy recipients. The value
proposition offered to the patient segment of the emerging economies by the current
technology available on market only marginally improves lifespan. Furthermore, it has
previously been shown that current heart valve technology fails faster and sooner as
patient age decreases [6, 8]. This implies that the marginal amount of engineering that
must be invested into each additional year of implant life increases as implant life
increases. Therefore, the much larger patient segment distribution exhibited by emerging
economy patient demographics will not be fully served by commercially available
technology currently and this sector will need technological innovation if it wants to
expand and capitalize on more patient segments. For a replacement valve to effectively
capture market share in these new market segments in emerging economies where most
of the human population resides and where there is the most clinical need, more robust
biomaterials must be designed coupled with computational modeling to optimize heart
valve design such that it has the lowest chances of failure modes at both the base
biomaterial level and device design level.
The basic question to implementing much needed technological advancement in this
sector of healthcare is how we can introduce value proposition to both developed markets
and emerging markets past the cannibalization of current product lines. How can we
design a valve that minimizes current market shareholder losses in adopting new
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technology and drive increased value in all the patient segments and geographical
segments. By designing a heart valve with increased implant life in many patient
segments and such that it leverages current heart valve supplier competencies is the
quickest way to market and drives the most social impact.
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CHAPTER TWO
2

PROJECT RATIONALE

Over 350,000 artificial heart valves are implanted each year domestically in the US
due to valvular stenosis, regurgitation, or congenital defects [1, 2, 4]. By 2050, this
volume is expected to increase to 850,000 annually just within the US [4]. However,
worldwide, there is precipitous demand of artificial heart valves in emerging economies
and this demand is in younger populations because the need for artificial valves in these
regions are driven by disease states such as rheumatic fever [2-4, 42]. With the increasing
demand on this life sustaining device, a more robust and durable biomaterial with higher
implant life is necessary for increased patient patency and quality of life.

2.1

Overview Gaps in Knowledge

The gold standard of heart valve implants is the bioprosthetic heart valve (BHV).
BHVs are the preferred option because they have optimal hemodynamic and do not need
the daily use of anticoagulants required for mechanical heart valves. With emergent
technology that enables BHVs to be implanted percutaneously with minimally invasive
surgery, it is possible to treat more elderly patients with BHVs. Mechanical valves can
only be implanted with traditional open heart surgery and valvuloplasty. The tradeoff
between BHVs and mechanical valves are in their failure rates. Both BHV and
mechanical valve failure rates start to occur 10-15 years after implantation [5, 10, 100];
however, BHV failure rates occur earlier younger patients sometimes as soon as 5-7 years
after implantation [7, 8]. The two main modes of failure in BHVs are calcification and/or
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structural degeneration leading to tearing [1-3, 60]. These two failure modes are not
mutually exclusive. BHVS can fail presenting with structural tears independent of
calcification or with calcification [97].
Because mechanical valves are engineered for total biological inertness, the implant
itself possesses a much longer lifespan than BHVs. However, anticoagulant therapy is
needed for the rest of the patient’s life because of the high incidence of thrombocyte
formation in mechanical valves [1, 3]. The use of these anticoagulants leads to long term
chronic problems in vital organs that can compromise the patient’s lifestyle. Mechanical
valves are also not good options for young women in child bearing ages because
anticoagulants are risky during pregnancy. MHV recipients experience increased stroke
risk and major bleeding events [10, 100].
Currently, BHVs recipients experience increased incidence of reoperation due to
structural degradation of the BHV [5, 10]. Therefore, the barrier to innovating the next
generation of heart valve replacements that addresses a larger patient segment is in
developing a biomaterial that can preserve optimal hemodynamics, has longer implant
lifespan in younger patients, and does not require the use of anticoagulants. One method
to accomplish this goal is in investigating alternative crosslinking methods used to
chemically treat tissue biomaterials for BHVs such as porcine aortic heart valve (PAV)
leaflets or bovine pericardium (BP) to produce a biomaterial that resists calcification and
structural degradation. Durable heart valves would minimize recurrent surgeries and
improve quality of life for patients.
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Major barriers to addressing calcification and structural degradation in BHVs are in
a limited understanding of the mechanisms of these failure modes. Though it has been
established historically in literature that calcification is a passive process of calcification
beginning from nucleation sites at cellular debris left in BHV materials [107, 108], it is
currently unknown as to how and why these nucleation sites manifest, how they
aggregate into stenosis inducing calcification nodules. There are conflicting views in the
literature on the role of the host cellular response in calcification. Although it has been
shown that alternative chemistries such as carbodiimide, epoxies, and other chemistries
yield calcification resistant biomaterials despite the cellular debris left in the implant, the
mechanisms are currently unknown indicating that there are more processes at play than
previously thought.
With regards to structural degradation through ECM degradation and mechanical
wear, much work has been done to look at mechanical wear and its effects on the tissue
composite. However, it is not explored as how alternative crosslinking chemistries and
the biomechanical implications of different crosslinking networks mitigates mechanically
induced structural degradation as well as what value can be added to BHV biomaterials
by retaining more native ECM components within the biomaterial. Furthermore, the
literature does not come to a cohesive consensus on the role of the host cellular response
in regards to structural degradation in terms of the extent of damage it can do to the
biomaterial microstructure as well as the implications of this damage. Though it is
accepted that mechanical fatigue can produce many deviations in biomechanics including
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flexural compliance [29, 93, 95-97, 99], others have also shown that the host cellular
response is capable of fragmenting ECM components [135, 138, 139].
Since the time of mass market implementation of the first glutaraldehyde valves 50
years ago, marginal increments of technological development on the BHV platform has
occurred at the biomaterial level. Though the two failure modes of calcification and
structural degradation have been well quantified in the clinical setting, only add-on anticalcification treatments have been developed over the years and now used on BHV
implants to resist calcific failure. Mechanisms of structural degradation of BHVs in
absence of calcification is not explored yet and little innovative features or add on
technologies in BHVs have been made to substantially reduce valve degeneration and
tearing. Furthermore, despite the knowledge of these earlier failure rates and modes,
glutaraldehyde persists to be the market gold standard and is used in the fabrication of the
BHVs.
This lack of innovation is most likely due to a gap in knowledge in how the
processes of calcification and structural degradation progresses and their causes. If the
triggers for structural degradation or calcification are known, especially if the host
cellular response is involved, then there can be a much more targeted approach for
material design in which specific chemistries can be selected to eliminate these triggers.
Gaining more insight into the exact action of mechanism of these failure modes can better
guide new biomaterials research in iterative design, validate viable biomaterials, and aid
in quickly screening out nonviable biomaterials. Such durable tissue biomaterials once
developed can also be used in variety of other applications.
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2.2

Research Aims

Aim 1: Development of a Novel Chemical Crosslinking Technique for
Improved Bioprosthetic Heart Valve
Developing a novel fabrication method to produce a more durable BHV biomaterial
would be useful in studying the mechanisms of structural degradation that are the
common failure modes for BHVs. This novel fabrication method will utilize a
combination of carbodiimide, neomycin, and PGG (TRI) to crosslink PAV leaflets and be
compared for efficacy in terms of durability and biocompatibility to glutaraldehyde
treated PAV leaflets. This novel crosslinking technique will be challenged for structural
integrity in its ability to resist ECM degradation via in vitro challenging with enzymes as
well as in vivo implantation in to small animals. This material will also be mechanically
tested for tear resistance as well as biaxial tensile testing to mechanically characterize the
tissue. Finally, this novel crosslinking method will be tested for in vivo biocompatibility
for 90 days in a subcutaneous rat calcification model.

Aim 2: Effects of Irreversible Chemistry on Durability of Tissue Based Materials
A novel method for fabricating BHV biomaterials (TRI) will be applied to bovine
pericardium to study the implications of using irreversible chemistry (as opposed to
reversible glutaraldehyde chemistry) on the resistance to degradation, mechanical
durability, and biocompatibility will be evaluated against glutaraldehyde treated bovine
pericardium. Resistance to degradation will be simulated via in vitro challenging with
enzymes as well as in vivo implantation in to small animals. This novel material will also
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be mechanically characterized through biaxial tensile testing for compliancy.
Additionally, mechanical durability will be tested via determination of peak stress to
cause rupture as well as a permanent set study in which a static load strain will be applied
to tissues. After this mechanical insult, biomaterials will be evaluated on its ability to
retain original geometry and permanent geometric deformation from static strain will be
determined. Furthermore, this novel biomaterial will be evaluated for biocompatibility
and resistance to calcification through a 30 Day subcutaneous rat calcification model.

Aim 3: Mechanisms of Calcification in Bioprosthetic Heart Valve Biomaterials in
Subcutaneous Rat Calcification Model
Underlying factors behind calcification from the literature are (1) cellular debris acting as
nucleation sites for calcification nodule formation, (2) degraded ECM protein
calcification, (3) inherent properties of glutaraldehyde crosslinking, (4) oxidative stress,
and (5) the host cellular response. A novel method for fabricating BHV biomaterials
(TRI) will be applied to bovine pericardium to study the underlying mechanisms of
calcification in BHV biomaterials. An additional study group in which we attempt to
isolate the calcification prone biomaterials from direct cellular contact will be utilized to
determine the roll of the host cellular response in calcification. Because we know that
TRI biomaterials are not calcification prone and ECM proteins do not degrade in vivo as
well as glutaraldehyde treated biomaterials heavily calcify and do not prevent the
degradation of ECM, TRI biomaterials will be pivotal in understanding the underlying
mechanisms of calcification. Gross histology and immunohistochemistry will be utilized
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to track cellular infiltration in and around implant groups as well as oxidative stress.
Calcification progression throughout the study will be monitored throughout the study via
qualitative histological assessment as well as mineral content quantification.
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CHAPTER THREE
3

SPECIFIC AIM 1: DEVELOPMENT OF A NOVEL CHEMICAL

CROSSLINKING TECHNIQUE FOR IMPROVED BIOPROSTHETIC HEART
VALVE MATERIALS

3.1

Introduction

Bioprosthetic heart valves (BHVs) are used to replace stenotic and regurgitant
heart valves [1, 2, 60]. BHVs do not require long-term anticoagulant therapy and also
have more optimal hemodynamics, thus making it the preferred option for valve
replacements. BHVs are fabricated out of two types of xenogeneic tissues: (1) Porcine
aortic valve (PAV) leaflets or (2) bovine pericardium sheet. Commercially available
BHVs fail due to structural degradation and/or calcification.
PAV leaflets resemble human heart valve leaflet three layered structure. The
fibrosa faces the aortic side of the leaflet and contains circumferentially aligned type I
collagen that provides strength to withstand high cyclic pressure environment [8, 60, 97].
Facing the opposite side towards the ventricle, the ventricularis contains radially aligned
elastin along with collagen. Elastic fibers are coupled with collagen bundles and brings
the collagen fiber structure back to a resting configuration between loading cycles, thus
the ventricularis provides elasticity and recoil to the leaflet [15, 18, 27, 172]. Between the
fibrosa and ventricularis lies the spongiosa that primarily contains glycosaminoglycans
(GAGs). This layer is assumed to mechanically function as a shearing medium between
the two other layers as the GAGs absorb water and form a hydrogel-like layer [27, 89,
160].

93

PAV’s are crosslinked with glutaraldehyde (GLUT) to fabricate BHV implants to
make them resistant against enzymatic degradation and less-immunogenic [1, 3, 135].
GLUT crosslinked BHVs tear and calcify after implantation, causing valve failure within
12-15 years of use [1-3, 60, 173]. Furthermore, calcification and structural degradation
seem to accelerate in younger patients most likely due to a more competent immune
system/increased metabolism and increased physical activity [1, 108]. Therefore, BHVs
are less frequently used for patients under 65 years of age. It should also be noted that
degeneration and calcification are not mutually exclusive and one can lead to the other.
GLUT crosslinking does not stabilize components such as elastin and GAGs of the heart
valve. Therefore, these major ECM components are lost from the tissue due to enzymatic
degradation [28, 34, 89, 144]. We have recently shown that GAGs in BHVs are strongly
connected with fiber-fiber and fiber-matrix interactions at low force levels and that they
may be important in providing a damping mechanism to reduce leaflet flutter when the
leaflet is not under high tensile stress [27]. Thus, the degradation of the essential ECM
components leads to the compromised mechanical function of the leaflet and this could
be a major contributor to degenerative tears of BHVs.
Here we have developed a novel tissue fixative method (TRI) that utilizes
carbodiimide, neomycin trisulfate, and pentagalloyl glucose (PGG) crosslinking
chemistry to stabilize all ECM components. We demonstrate that PAV leaflets treated
with TRI improve tear toughness, resist in vivo calcification, structural degradation, and
are more biocompatible than GLUT treated leaflets.
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3.2
3.2.1

Methods

Heart valve material preparation

Porcine aortic heart valves (PAVs) were harvested fresh from a local slaughter
house and transported on 0.9% saline and ice to the laboratory. Whole PAVs were
washed in 0.9% saline for 15 minutes. The leaflets were then cut from the aortic root and
washed in 0.9% saline for 3 to 5 minutes. These leaflets were then treated with two
different chemical treatment techniques: (1) GLUT – control and (2) TRI – newly
proposed crosslinking technique.
GLUT: Fresh leaflets were treated with 0.6% glutaraldehyde in 50 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (pH 7.4) at room
temperature with gentle shaking for 24 hours, solution decanted, and replaced with 0.2%
glutaraldehyde in 50 mM HEPES buffered saline (pH 7.4) and the crosslinking was
continued for at least six days [172].
TRI: Fresh leaflets were treated with 0.5 mM neomycin trisulfate solution in 2(N-morpholino) ethanesulfonic acid (MES) buffer for 1 hour. The solution was decanted
and leaflets were then incubated in a 30 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) / 0.05% PGG solution in
50 mM MES buffered saline (pH 5.5) for twenty-four hours. The solution was decanted
and then the leaflets were crosslinked further in 30 mM EDC and 6 mM NHS solution in
50mM MES buffered saline (pH 5.5) for 24 hours. Following fixation, valves were
placed in 20% isopropanol in 50 mM HEPES buffer (pH 7.4) for at least six days.
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3.2.2

Differential scanning calorimetry

Differential scanning calorimetry (DSC) was used to measure the thermal
denaturation temperature (Td) of collagen. Samples (3-8 mg) from each of the TRI and
GLUT groups were carefully cut from generally the same region of the leaflet, blotted
dry, and placed flat in hermetically sealed pans. Samples were tested using a DSC 2920
(TA Instruments, Newcastle, DE). A pilot run verified the Td range for GLUT compared
to previous results, and the remainder of samples were equilibrated at 20 ºC, and heated
at 10 ºC/min. The denaturation temperature was recorded as the maximum value of the
endotherm peak.

3.2.3

Enzymatic challenge studies

3.2.3.1 Resistance to collagenase and elastase
PAV leaflets were cut in half symmetrically, rinsed in nanofiltered water, blotted
dry, frozen, lyophilized, and weighed. Half leaflets were incubated in 1.2 mL of 5 U/mL
porcine pancreatic elastase (Elastin Products Co. Inc., Owensville, MO) in 100 mM Tris,
1mM CaCl2, 0.02% NaN3 (pH 7.8) for 24 hours, or 75 U/mL collagenase (Type I, Sigma,
St. Louis, MO) in 50 mM Tris, 10 mM CaCl2, 0.02% NaN3 (pH 8.0) for 48 hours at 37oC
while shaking at 650 RPM while other half was incubated with buffer only. Enzyme
liquid was saved for further studies, digested cusps rinsed in nanofiltered water, blotted
dry, frozen, lyophilized, and weighed. Percent weight loss was calculated. For storage
studies, samples were stored for 21, 60, or 180 days in 0.2% glutaraldehyde solution
(GLUT samples) or 20% isopropanol in HEPES buffer (TRI samples), taken out of
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storage, washed in saline 3x for 15 minute, and challenged with the aforementioned
protocol with collagenase or elastase and percent weight loss calculated.

3.2.3.2 Resistance to GAGases
PAV leaflets were carefully excised from the aortic wall, and washed thoroughly
in 100 mM ammonium acetate buffer (AAB) at pH 7.0 3x for 5 minutes. Leaflets were
cut symmetrically, one half incubated in 1.2 mL GAG degrading enzyme solution (5
U/mL hyaluronidase (Sigma, St. Louis, MO), 0.1 U/mL chondroitinase (Sigma, St. Louis,
MO) in 100 mM AAB, pH 7.0) while the other half incubated in AAB. Samples were
shaken vigorously for 24 hours at 37oC. Following 24 hours incubation, leaflets were
washed in distilled water 3x for 5 min, frozen, and lyophilized. Total hexosamine
content was measured using the hexosamine assay as previously reported [172]. Elson
and Morgan’s modified hexosamine assay was used to measure GAG-related
hexosamines [28]. Lyophilized GAG digested samples were weighed, digested in 2 mL 6
N HCl (24 hours, 96 degrees C), and dried under nitrogen gas.

Samples were

resuspended in 2 mL 1M sodium chloride and reacted with 2 mL of 3% acetyl acetone in
1.25 M sodium carbonate. 4 mL ethanol and 2 ml of Ehrlich’s reagent (0.18M pdimethylaminobenzaldehyde in 50% ethanol containing 3N HCl) were added, and
solutions left for 45 min to allow the color to develop. A pinkish-red color is indicative
of tissue hexosamine quantities, and the absorbance was read at 540 nm. A set of D(+)glucosamine standards were used. For storage studies, samples were stored for 21, 60, or
180 days in 0.2% glutaraldehyde solution (GLUT samples) or 20% isopropanol in
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HEPES buffer (TRI samples) taken out of storage, washed in saline 3x for 15 minute, and
challenged with the aforementioned protocol with collagenase or elastase and percent
weight loss calculated.

3.2.4

Mechanical testing

Tissue specimens (n = 7 per group) were tested under biaxial tension using a
custom-built biaxial device [174, 175]. Roughly 1 cm by 1 cm sections were taken from
the central belly region of the leaflets and mounted to the device with the circumferential
and radial directions along the device axes. The specimens were then loaded to a
maximum membrane tension of 60 N/m over a period of 15s following a preconditioning
step [140, 176]. The strain was determined via four fiducial markers were glued to the
central region of the specimen [140]. All mechanical testing were performed in PBS at
room temperature.

3.2.5 Suture pull-out testing
PAV leaflets were evaluated for structural integrity and its ability to resist tearing.
Fresh, GLUT, and TRI, leaflets were cut with a die in rectangular 40mm x 4.0mm
sections and were then treated with GAGase, porcine pancreatic elastases, or no enzyme
treatment (n = 10, 9 groups total). For suture pull-out test, half of the samples were
oriented circumferentially (with collagen alignment) and half samples were aligned
radially (perpendicular collagen alignment). One side of tissue samples was attached to
a bottom clamp in a tensile tester (MTS, Minneapolis, MN). A single suture
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(Polypropylene blue monofilament 4-0 P-3 Ethicon™, San Lorenzo, Puerto Rico) was
pierced through the sample a third of the way down the sample and was clamped to the
top clamp. Samples were tensile tested at 12 mm/min to determine the amount force (N)
it took to pull the suture out of the sample. The peak load, thickness of the sample, and
width were used to calculate cross sectional area to determine stress. Tested samples were
embedded in paraffin blocks and sectioned for alcian blue staining and movat’s
pentachrome staining to visualize ECM components.

3.2.6 In vivo calcification model
Following fixation, all tissues were rinsed thoroughly three times in 30 minute
washes of sterile saline, and remained in sterile saline until implantation. Male juvenile
Sprague-Dawley rats were anesthetized by inhalation of 3% isoflurane gas. A dorsal
surgical incision was made, and two subdermal pockets created on either side of the
sagittal plane. Cusps were blotted and positioned to lie as flat as possible in the pocket.
One cusp was placed per pocket. Incisions were closed with surgical staples and samples
with fibrous capsule still intact were retrieved after 30 or 90 days implantation. Blood (2
mL) was drawn from the rats before euthanasia with CO2 asphyxiation. The leaflets with
surrounding capsule were removed from the subdermal sites. The middle section was
saved for histological analysis. The remaining sections were placed immediately on dry
ice, and frozen at -80°C as soon as possible.
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3.2.7

Mineral analysis

Half cusps (without the capsule) from subdermal implantation studies were
frozen, lyophilized, weighed, and acid hydrolyzed in 2 mL 6N Ultrex II HCl for 20 hours
at 96ºC. Samples were dried under nitrogen gas, resuspended in 1 mL 6N Ultrex II HCl,
and centrifuged at high speeds to separate any remaining particles. Samples were diluted
1:50 in nanofiltered water, Calcium and phosphorous content in samples were analyzed
using the Spectro Acros ICP Spectrometer (SPECTRO Analytical Instruments, Kleve,
Germany) at Clemson University Agricultural Service Laboratory. Dilution ratios were
used to calculate element content of the sample, and values were normalized to dry
sample weight.

3.2.8

Histology

Radial cross sections were taken from the center of cusps, stored in formaldehyde,
processed, embedded in paraffin, and sectioned at 6 μm for light microscopy analysis.
Movat’s pentachrome and alcian blue stains were utilized to visualize and assess ECM
content. Dahl’s alizarin red stain with light green counterstain was used to visualize
calcium deposition in implanted samples; calcium deposits appear red. Hematoxylin and
eosin staining was used to visualize and assess the cellular response to implants.
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3.2.9 Statistical Analysis
Results are expressed as means ± standard errors. Statistical analysis was
performed using one-way analysis of variance (ANOVA). Differences between means
were determined using the least significant difference with an alpha value of 0.05.

3.3
3.3.1

Results

Enzyme stability studies

We determined the thermal denaturation temperatures (Td) of the tissue with DSC.
Td has been shown to effectively correlate with tissue collagen stabilization [172]. Both
GLUT and TRI treated leaflets showed adequate increase in Td (88 ± 1.2oC or 89 ± 0.9oC,
respectively compared to fresh tissue 56± 3.2 oC [172]), suggesting complete collagen
stabilization (Figure 3-1A).
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Figure 3-1. Initial ECM stability of crosslinked porcine aortic valve leaflets. (A) DSC
analysis determining denaturing temperature of GLUT or TRI treated leaflets. Fresh,
GLUT, or TRI samples were challenged with (B) collagenase or (C) elastase and percent
mass lost was utilized to determine biochemical effectiveness of crosslinking (n = 6). (D)
GLUT or TRI treated leaflets were challenged with GAGase or buffer solution and
hexosamine content was utilized to determine GAG stability. *Indicates significant
difference (p<0.05) from GLUT.

When GLUT or TRI treated leaflets were challenged with type I collagenase,
1.52% ± 1.07 or 0.42% ± 0.42 mass loss, respectively, was exhibited while fresh leaflet,
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with no stabilization by crosslinking lost almost 70% of its weight as expected (Figure 31B). No significant difference was detected between GLUT and TRI treated leaflets
indicating that collagen within the PAV leaflets was adequately protected from simulated
enzymatic degradation in both crosslinking methods.
When GLUT or TRI treated leaflets were challenged with porcine pancreatic
elastase, elastin within the PAV leaflets was not protected in GLUT treated leaflets but
was protected in TRI treated leaflets from simulated enzymatic degradation (16.89% ±
2.14 vs. 4.60% ± 1.87 mass loss, respectively, p < 0.0001) Figure 3-1C). When GLUT
treated leaflets were challenged with GAGase enzyme cocktail, 54% loss of GAGs was
found as compared to control buffer treatment (110.50 ± 11.14 vs. 241.71± 10.22 μg
sulfated GAGs/10 mg tissue respectively, p < 0.0001, Figure 3-1D). However, TRI
treated leaflets did not lose significant amounts of GAGs when challenged with GAGase
(265.19 ± 16.91 vs. 286.32± 19.05 μg sulfated GAGs/10 mg tissue respectively, p > 0.05,
Figure 3-1D). This clearly suggested that TRI treatment stabilizes GAGs within the
leaflets.

Figure 3-2. Long-term crosslinking stability of crosslinked porcine aortic valve leaflets.
GLUT or TRI™ treated leaflets were challenged with (A) collagenase or (B) elastase and
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percent mass lost was utilized to determine biochemical effectiveness of crosslinking at
0, 21, 60, or 180 days (n = 6). (C) GLUT or TRI™ treated leaflets were challenged with
GAGase and hexosamine content was utilized to determine GAG stability at 0, 21, 60, or
180 days (n = 8). *Indicates significant difference (p<0.05) from GLUT.

We next determined the storage stability of the leaflet stored in 0.2% GLUT or
20% ispropanol for 21, 60, or 180 days. Weight retention after challenging with
collagenase or elastase after storage illustrated the biochemical stability of GLUT or TRI
treated leaflets (Figure 3-2A and 3-2B, respectively). No significant change in weight
was found with reference to t = 0 days in GLUT and TRI samples when challenged with
collagenase (Figure 3-2A); however, GLUT treated tissues exhibited a significant
decrease in weight after elastase treatment at each time point (Figure 3-2B) and lost
GAGs (Figure 3-2C). Significantly lower weight loss after elastase was found in TRI
treated samples (Figure 3-2B). No decrease in GAG content was detected at any time
point as compared to t = 0 in TRI tissues (Figure 3-2C). This data demonstrates the
efficacy of our storage solution to maintain ECM stability during storage of TRI treated
BHVs.
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3.3.2

Planar biaxial biomechanics

Figure 3-3. Equibiaxial mechanical testing on GLUT and TRI treated leaflets (n = 7). (A)
The mean equibiaxial mechanical response is show with the the standard error of the
mean. (B) The area stretch at 60 N/m to show compliance in GLUT and TRI treated
leaflets. (C) Thickness of the specimens.

Both GLUT and TRI exhibited a nonlinear anisotropic response under equibiaxial
tension typical of valvular tissue (Figure 3-3A). We found a significant difference in the
overall compliance between the two groups (areal stretch of 1.699 ± 0.082 and 1.465 ±
0.048 for GLUT and TRI respectively (p < 0.036), Figure 3-3B). The difference in radial
stretch itself was not statistically significant (p < 0.678). There was no statistical
difference in thickness measured, 0.846 ± 0.069 and 0.904 ± 0.066 respectively (Figure
3-3C), and general differences in leaflet shape and geometry was not observed.
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3.3.3

Resistance to tearing

Figure 3-4. Resistance to tearing in Fresh, GLUT, or TRI treated leaflets subjected to no
enzymatic treatment, GAGase, or elastase (6 groups, n = 8 for each group). (A) Peak
stress to cause tearing toughness. (B – G) Alcian blue staining on Fresh, GLUT, or TRI
treated leaflets subjected to no enzymatic treatmen or GAGase. GAGs are stained blue
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and nuclei are counterstained red. (H – M) Movat’s pentachrome staining on Fresh,
GLUT, or TRI treated leaflets subjected to no enzymatic treatmen or elastase. Collagen
and elastin are stained yellow and black, respectively. *Indicates significant difference.
A suture pull-out test was used to evaluate the biomaterial’s ability to resist
tearing. Before enzymatic treatment with GAGase or elastase, Fresh samples required
583.0 ± 59.1 MPa of peak stress to cause the suture to pull out of the tissue (Figure 34A). After treatment with GAGase, the peak stress required to cause suture pull out was
reduced to 429.5 ± 21.1 MPa (p < 0.019) (Figure 3-4A). After treatement with elastase,
the peak stress required to cause suture pull out was 505.9 ± 33.5 MPa; however, was not
significantly reduced (p < 0.141) (Figure 3-4A). Post treatment with GAGase and elastase
resulted in loss of GAGs (Figure 3-4C) and elastin (Figure 3-4I) as evident by significant
reduction in alcian blue staining for GAGs and fragmentation/absence of an extensive
black fibrous network of elastin fibers in VVG stain when compared to controls (Figures
3-4B and 3-4H, respectively). GLUT samples required 528.1 ± 35.0 MPa of peak stress
to cause the suture to pull out of the tissue (Figure 3-4A). After treatment with GAGase,
the peak stress was reduced to 303.4 ± 13.7 MPa (p < 0.0002) (Figure 3-4A). After
treatement with elastase, the peak stress was reduced to 377.0 ± 24.9 MPa (p < 0.004)
(Figure 3-4A). Post treatment with GAGase and elastase resulted in loss of GAGs (Figure
4E) and elastin (Figure 3-4K) and as evident with histological stains when compared to
controls (Figures 3-4D and 3-4J, respectively). Before enzymatic treatment with GAGase
or elastase, TRI samples required 667.3 ± 57.7 MPa of peak stress to cause the suture to
pull out of the tissue (Figure 3-4A). After treatment with GAGase or elastase, the peak
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stress was not significantly reduced (565.5 ± 37.9 MPa, p < 0.106 and 612.2 ± 36.9 MPa,
p < 0.243 respectively, Figure 3-4A). GAGase and elastase did not digest GAGs (Figure
3-4G) and elastin (Figure 3-4M) and their presence was evident in alcian blue staining for
GAGs and extensive network of elastin fibers in VVG stain when compared to controls
(Figures 3-4F and 3-4L, respectively). This suggests an increased resistance to tearing
was possibly due to the protection of the integrity of ECM components for the TRI
crosslinking protocoI.

3.3.4

Calcification and biocompatibility of crosslinked leaflets

Figure 3-5. Histological characterization of host cellular response and ECM integrity of
GLUT or TRI treated porcine aortic valve leaflets pre or post in vivo implantation into
male juvenile rats for 90 days. (A – D) Hemotoxylin and Eosin staining. Nuclei are
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stained purple and cytoplasm is stained pink. Calcification nodules are granular and
stained deep purple. Black bar indicates 200µm and 50µm in insets, respectively. (E – H)
Movat’s Pentachrome staining. Fibrous elastin is stained black or dark purple. Black bar
indicates 50µm. (I – L) Alcian blue staining. GAGs are stained blue and nuclei are
counterstained red. Black bar indicates 200µm.

Leaflets were implanted subdermally in rats for 90 days to study calcification
tendancy and biocompatibility. After implantation, GLUT treated leaflets presented with
a thick fibrous capsule formation surrounding the implant with persistance of host
cellular activity indicative of a moderate to high inflammatory response (Figure 3-5B).
TRI treated tissues presented with minimal fibrous capsule formation (Figure 3-5D) and
no persistance of host celluar response indicative of more biocompatible implant (Figure
3-5D). Unimplanted leaflet histology is depicted in Figure 3-5 A and C.
Movat’s pentachrome staining and Alcian Blue staining on GLUT leaflets
indicated a loss in ECM specifically in elastin and GAG content during implantation as
compared to unimplanted leaflets (Figure 3-5F and Figure 3-5J, respectively). Note that
the elastin fibrous network in the post-implant in GLUT leaflets demonstrate chopped
and feathered rather than the long continuous networks indicative of loss of functional
elastin (Figure 3-5F). Furthermore, note that the GLUT leaflets were so heavily calcified
that the section suffered from much fretting on the microtome and did not effectively take
up the Alcian Blue stain (Figure 3-5J). TRI treated tissues retained ECM components
such as elastin and GAGs much more robustly after implantation (Figures 3-5H and 3-5L,
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respectively). Unimplanted samples are depicted in Figure 3-5 E, G, I, and K for
comparison.

Figure 3-6. Mineralization characterization in crosslinked porcine aortic valve leaflets
pre or post in vivo implantation into male juvenile rats for 90 days. (A – D) Alizarin red
staining for calcification deposits (red) counterstained green after 90 days implantation.
Black bar indicates 200µm. (A) Preimplantation GLUT. (B) Preimplantation TRI. (C)
Postimplantation GLUT. (D) Postimplantation TRI. (E) ICP quantification of GLUT or
TRI treated PAV leaflets after 90 days in vivo implantation of calcium and phosphorus
mineral content (n = 6). *Day 0 implants had no detectable amount of mineralization.
*Indicates significant difference.

Alizarin red staining on GLUT treated leaflets showed no calcification before
implantation and heavy calcification after 90 days implantation (Figure 3-6A and 3-6B,
respectively). Alizarin red staining on TRI treated leaflets showed no calcification before
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implantation and no calcification after implantation (Figure 3-6C and 3-6D, respectively).
This was further confirmed with quantitative calcium and phosphorus analyses with ICP
(Figure 3-6E). Pre implant samples exhibited non detectable amounts of mineralization.
At 90 days, GLUT samples were found to contain 106.0±3.68 µg/mg of dry tissue of
calcium and 48.40±1.6 µg/mg of dry tissue of phosphorus. TRI samples were found to
contain 9.00±1.71 µg/mg of dry tissue of calcium and 2.48±0.83 µg/mg of dry tissue of
phosphorus. Significant differences between explanted GLUT and TRI leaflets
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calcium and phosphorus content (p < 0.0001 and p < 0.0001, respectively) were found
after 90 days implantation.

3.4
3.4.1

Discussion

Pitfalls of glutaraldehyde crosslinking

For the past forty years, GLUT has been used to crosslink tissues to render them
stable and less immunognic for implantation into the human body. By crosslinking
neighboring amine groups through a Schiff-base reaction, highly immunogenic epipitotes
are masked from the immune system [84, 141]. GLUT crosslinked tissues are shown to
calcify and degenerate and fail within 12 – 15 years after implantation [1-3, 60]. BHV
failure related to calcification and tissue tearing can occur simultenously or separately.
For example, more than fifty percent of failed valves show degeneration and tears but no
calcification while fifty percent failed valves show heavy calcification making valves
stiff and incompetent but without tissue tears [97, 177].
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Thus, to improve durability of BHVs, both calcification and structural
degeneration needs to be prevented.

Several anti-calcification strategies such as

treatments with surfactants, chelation reagents, and alcohols have shown prevention of
calcification of BHVs in animal models and few of them are now used commercially in
clinical settings [149, 150, 178]. Due to short time span of valve implants with anticalcification treatments in humans (5-7 years), it is still awaited if such treatments make
valves more durable. Even if anti-calcification treatments work to prevent calcification,
structural degeneration also needs to be prevented as many valves fail clinically due to
degenerative tissue tears without calcification.
Previous research has indicated that glutaraldehyde crosslinking itself may
increase propensity of tissue calcification [109, 110]. Schiff-base crosslinking [85, 141] is
shown to be reversible and susceptible to hydrolysis [85, 142]. Though the reaction can
be made more irreversible by using reducing agents such as sodium tetraborate [143];
such treatments are not used for clinical BHVs. Inability of GLUT crosslinking to stop
degradation of the integrity of the collagen triple helix during cyclic fatigue loading was
shown by shifts in amine peaks in FT-IR experiments [29]. Same studies also showed
that in vitro cyclic fatigue casues change in bending stiffness GLUT treated PAVs
indicating a degradation of the ECM structure [29]. Glutaraldehyde only actively
crosslinks collagen and leaves other key ECM components such as GAGs and elastin
unstabilized in the overall tissue composite [141]. Elastin and GAGs that play crucial
roles in the biomechanics of the native heart valve tissue are left open to proteolytic
degradation by both host and endogenous enzymes as well as constant mechanical
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fatiguing of the tissue [18, 28, 144, 157, 159, 172]. Slow depletion of these ECM
components compounded with constant cyclic loading may lead to microtears after valve
implantation. This early degeneration may then lead to calcification nodule development
and/or visible tears within a few years. Our current data clearly showed that GLUT
crosslinking did not stabilize GAGs and elastin in the tissue and caused more
inflammatory response after implantation and heavy tissue calcification after
implantation. Perhaps retaining these other ECM components by using them as active
substrates for crosslinking chemistry will enable more prolonged stabilization and
promote a better functional, more durable biomaterial in the long term to enable extended
implant life.
We show here that by using the novel crosslinking technique (TRI), a more robust
and durable BHV could be obtained.

3.4.2

TRI, a new crosslinking method for ECM stability

TRI uses a combination of carbodiimide crosslinking chemistry, neomyocin, and
PGG. Carbodiimide chemistry has been used previously to attach functional groups to
surfaces of polymers [179-181].Carbodiimide is a zero length crosslinker meaning it
allows linking neighboring carboxyl and amine groups in proteins to create amide bonds
[179]. Carbodiimide has previously been used alone to stabilize heart valve prosthetics
with the intent of decreasing calcification [153]; however, carbodiimide crosslinking
treatments pertaining to heart valve biomaterial fabrication was not clinically pursued.
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This was probably due to degenerative failures of these valves during early development
due to insufficient crosslinks.
Neomycin historically has been used as an antibacterial agent; however,
neomycin is also an effective hyalaronidase inhibitor [144]. Hyaluronic acid serves as the
backbone of the aggrecan molecules of GAGs that make up much of the spongiosa in
PAVs. GAGs are highly hydrated and are important to valve function as they mediate
low force tension and fiber-fiber orientation [27]. If this backbone is stabilized, GAGases
are unable to hydrolyze proteoglycans thus increasing the retention of GAGs in the ECM.
By using neomycin in conjunction with a crosslinker that utilizes amine groups for
crosslinking such as glutaraldehyde or carbodiimide, neomycin can be incorporated into
the crosslinking scheme sustained protective effect to prevent GAG loss [144, 157, 159,
160, 172]. This protective ability for neomycin towards GAGs has been previously
demonstrated in our laboratory in which tissues treated with neomycin combined with
glutaraldehyde reduced GAG loss during enzymatic treatment and this retention in GAGs
reduced the tissue’s propensity to buckle compared to glutaraldehyde only treated tissue
[160]. Furthermore, tissues treated with neomycin and carbodiimide chemistry has
previously been demonstrated to prevent GAG loss during enzymatic treatment and this
retention has shown similar biomechanics to GLUT valves [159]. However, neomycin
treatment was unable to stabilize elastin, another important component of the ECM [160,
172].
Veseley et al demonstrated the key biomechanical roles that elastin plays in the
heart valve leaflet [15, 18, 81]. A large deviation and a loss of elasticity particularly in
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compliance of the valves were noted in tissues that were depleted of elastin [18]. PGG is
a tannic acid derivative that has been shown previously to stabilize elastin in aortic root
[34, 113, 170, 172]. PGG is believed to physically interact with the hydrophobic domains
of elastin thus blocking cleavage sites for elastases such as matrix metalloproteinases
(MMPs) and cathapsins [34, 113, 170, 182]. This interaction is also believed to block
deposition sites for calcification [155, 170]. Tripi et al combined PGG with neomycine
treatment and noted a retention of GAGs and elastin when challenged enzymes; however,
due to gluratarldehyde crosslinking calcification of the valve was not prevented [172].
In present work, we combined neomycine, PGG, and carbodimide chemistries to
create TRI crosslinking. Carbodiimide was used to replace GLUT, neomycin was used to
protect GAGs, and PGG was used to protect elastin. Collectively, this novel treatment
technique created a more robust stabilization of the entire composite through an
irreversible meshwork of crosslinks. We show the improved efficacy of tissue composite
stabilization at the biochemical level of this combination of stabilizing agents using
enzymatic challenges. Collagen, GAGs, and elastin were all stabilized with this
crosslinking chemistry when challenged with enzymes specifically targeting these ECM
components (Figure 3-1). We also demonstrated this ECM stability over an extended
period of storage time of up to six months (Figure 3-2). This is important as tissue heart
valve implants need to have prolonged storage life. GLUT treated BHVs showed no
protection of elastin or GAGs during storage and this may be one of the reasons for BHV
failure within few years found for currently clincally used GLUT treated valves.
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3.4.3

TRI vs GLUT biomechanics

Our biomechanical results for GLUT treated leaflets match closely to prior results
[88, 157] with the maximum areal stretch being ~1.7 for both directions. Subtle
differences may arise due to slight variations in tissue preparation. We do however note
that there is a significant difference between TRI and GLUT. This was expected
considering that TRI leaflets have a higher level of crosslinking. We also note that the
main differences in strain occur in the low stress region of the leaflet (T < 10 N/m)
similar to Friebe et al.’s study on neomycin-glutaraldehyde crosslinked valves [157].
Based on conventional theories involving collagenous tissue [140, 174, 175], collagen
fibers are crimped structures that bear nearly no load until straightened. Thus, in this
region collagen is mostly undulated and the load bearing contribution comes from
remaining ECM structures such as elastin, proteoglycans and GAGs. Thus increase in
strain at lower stress region in TRI leaflets may be a result of a more extensive ECM
stabilization. The exact contribution from each ECM component is not known and
requires rigorious analysis via constitutive modeling. However, we do note that the nonlinear/exponential like behavior and anisotropy of the leaflet remain similar to GLUT
treated tissues. Furthermore, there is no statistical difference in thickness measured after
the treatments (Figure 3-3C) which suggests that TRI does not produce a drastic change
in leaflet geometry. This suggests that the leaflets will experience similar stress during
physiological loading. We also note from observation that there is no visible difference
between the leaflets at a tissue level, except slight discoloration in GLUT leaflets as
compared to white TRI leaflets. As such, the mechanical differences are a result of the
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mechanism at the fiber (elastin and collgen fiber composition) and molecular
(crosslinking bounds) scale. Long-term cyclic fatigue results are underway to see if TRI
treatment makes tissue more fatigue resistant.

3.4.4

TRI vs GLUT tear stress test

It is important to note that treatment crosslinkers although make tissues an order
of magnitude stiffer than fresh tissues, crosslinking does not have a statistically
significant effect on the suture pull out stress, clearly suggesting tearing between collagen
bundles.
The suture pull out study suggests that retaining key ECM components such as
GAGs or utilizing a more extensive crosslinking chemistry in lieu of glutaraldehyde may
enable a biomaterial to resist tear formations by preventing shunting between collagen
fibers and thus resist the process of structural degradation, one of the main failure modes
of BHVs to date.
The data suggested that losing GAGs within the tissue composite decreases the
biomaterial’s resistance to tearing demonstrated by the reduction of peak stress to cause
tearing in both Fresh and GLUT leaflets after treatment with GAGase enzyme. However
when GAGs are actively retained in the material using the TRI treatment, treatment with
GAGase produced no significantly reduction in peak stress to cause suture pull out
(Figure 3-4). This may be due to GAGs playing a roll in ECM-ECM component
coordination and acting as articulation points between ECM components such as
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collagen-collagen interactions [27]. Retaining this structure may provide for a more
robust biomaterial that resists tearing.
In the GLUT samples, treatment with elastase significantly reduced the peak
stress required to cause suture pull out. Therefore, elastin loss may shunt stress more
quickly along collagen bundles in GLUT crosslinked tissues as comapred to fresh
uncrosslinked leaflets. Fresh tissues did show reduction in peak stress for suture pull out
after elastase but it did not reach statistical significance. TRI on the other hand
demonstrated no statistical significat reduction in peak stress required to cause suture pull
out due to elastin stabilization again showing elastin stabilization can also aid in
preventing tissue tearing. To our knowledge, this is the first time anyone has tested for
tear resistance of bioprosthetic heart valve biomaterials and its dependence on ECM
crosslinking.

3.4.5

TRI vs GLUT stabilization in vivo study

Research indicates that glutaraldehyde may not be as tolerable long-term to the
body [84, 117, 135, 183]. As Schiff base bonds are degraded, free aldehyde molecules
created could be released that could activate additional host cellular response [117, 118,
134, 136]. We evaluated the retention of key ECM components (collagen, elastin, and
GAGs) and biocompatibility after subcutaneous implantation into a rat model (Figure 35). GLUT treated leaflets experienced complete fragmentation of the elastin fibers and
complete depletion of GAGs. This depletion of ECM could be a large contributing factor
to structural degradation of GLUT treated valves. On the other hand, TRI treated leaflets
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showed retention of collagen, elastin, and GAGs. In addition, TRI treatment effectively
curbed calcification of BHV tissue compared to glutaraldehyde treated tissues after
subcutaneous implantation for ninty days. No signs of calcification were found in the
alizarin red staining in TRI treated valves (Figure 3-6). GLUT samples presented with
intense red staining with Alizarin stain indicative of precipitous calcification in all layers
of the leaflet. This accumulation of calcification deposition in the subcutaneous rat model
corresponds to over 10 years of clinical implantation [108].
When implanted subdermally, GLUT tissues showed thick fibrous capsule
formation around the implant with many inflammatory cells. TRI presented with minimal
fibrous capsule formation with minimal cellular activation present. This data clearly
suggests that due to stable crosslinks in TRI, ECM compoments and unstable crosslinkers
do not leach out and cause inflammatory response as seen in GLUT tissues.

3.4.6

Limitations of study

Although we show improved crosslinking and stability of TRI treated leaflets to
enzymatic degradation in vitro and complete resistance towards calcification after
subdermal implantation, more studies are needed establish the viability and functionality
in vivo under long term cyclic strain. This includes demonstrating the efficacy of the this
novel biomaterial via accelerated in vitro fatigue testing. Furthermore, these valves need
to be examined in large animal studies by implanting as heart valve replacements to
assertain their function and resistance to degeneration and calcification under blood
contact. By gaining more insight into this novel technique and optimizing the treatment to
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produce superior durability and biomechanical behavior, a more robust BHV can become
commercially viable.

3.5

Conclusions

A novel treatment technique for BHV fabrication, TRI, has been shown to
produce a biomaterial that is less susceptible to enzymatic structural degradation, tearing,
and calcification. Furthermore, the data suggest that TRI produces a more biocompatible
material than glutaraldehyde treated tissues. Such newly developed biomaterial may
provide more durable heart valve implants in future.
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CHAPTER FOUR
4

SPECIFIC AIM 2: EFFECTS OF IRREVERSIBLE CHEMISTRY ON BHV
BIOMATERIAL DURABILITY
4.1

Introduction

Bioprosthetic heart valves (BHVs) are used to replace stenotic and regurgitant
heart valves [1, 2, 60]. BHVs do not require long-term anticoagulant therapy and also
have more optimal hemodynamics, thus making it the preferred option for valve
replacements [1, 184]. BHVs are fabricated out of two types of xenogeneic tissues: (1)
Porcine aortic valve (PAV) leaflets or (2) bovine pericardium (BP) sheet. Commercially
available BHVs fail due to structural degradation and/or calcification [1, 60].
BP is the most commonly used material to fabricate BHVs and contains a high
amount of layered structural proteins (collagen and elastin with proteoglycans) to impart
viscoelastic properties to the tissue composite. BP patches are selected based on thickness
(0.5 mm) but it is not common industry practice to select for any type of preferred
orientation despite previous literature suggesting there are preferred orientations of
isotropy and deviations in fiber orientation in these preferred orientations have been
correlated with accelerated fatigue induced structural degradation in valve materials [93,
94, 96].
Selected BP sheets are crosslinked dropwise with glutaraldehyde (GLUT) then cut
into custom strips to fit around onto sewing rings to fabricate BHV implants. This
process allows BHV tissues to maintain native load bearing structures such as collagen
and renders them implantable into the body while maintaining native-like structure [1-3,
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185]. However, GLUT crosslinked BHVs tear and calcify after implantation, causing
valve failure within 12-15 years of use [1, 2, 8, 60]. Furthermore, calcification and
structural degradation seem to accelerate in younger patients most likely due to a more
competent immune system/increased metabolism and increased physical activity [8].
Therefore, BHVs are less frequently used for patients under 65 years of age. It should
also be noted that degeneration and calcification are not mutually exclusive and one can
lead to the other [60]. GLUT crosslinking does not stabilize components such as
glycosaminoglycans (GAGs) and elastin. Therefore, these ECM components are lost
from the tissue due to enzymatic degradation [172, 186-188]. Such degradation of the
essential ECM components leads to the compromised mechanical function of the leaflet
[15, 18, 160] and this could be a major contributor to degenerative tears of BHVs.
Here we demonstrate a novel, crosslinking method (TRI) that utilizes
carbodiimide, neomycin trisulfate, and pentagalloyl glucose crosslinking chemistry to
stabilize all ECM components within BP. We demonstrate that BP tissues treated with
TRI are more compliant and have significantly improved tear toughness. TRI BP tissues
also do not exhibit as drastic permanent set effects as GLUT BP tissues. The data
suggests that irreversible crosslinking chemistries such as TRI can produce significantly
more durable and calcification resistant biomaterials for BHV fabrication.
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4.2
4.2.1

Methods

Fabrication of tissue based biomaterials

Bovine pericardium (BP) was sourced from a third party abattoir, delivered on 0.9%
saline and ice to the laboratory. BP sacs were cut into flat sheets and were washed in
0.9% saline for 15 minutes. BP sheets were then treated with two different chemical
treatment techniques: (1) GLUT – control and (2) TRI – novel, more irreversible
crosslinking technique.
GLUT: BP sheets were treated with 0.6% glutaraldehyde in 50 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (pH 7.4) at room
temperature with gentle shaking for 24 hours, solution decanted, and replaced with 0.2%
glutaraldehyde in 50 mM HEPES buffered saline (pH 7.4) and the crosslinking was
continued for at least six days.
TRI: BP sheets were treated with 0.5 mM neomycin trisulfate solution in 2-(Nmorpholino) ethanesulfonic acid (MES) buffer for 1 hour. The solution was decanted and
leaflets were then incubated in a 30 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) / 0.05% PGG solution in
50 mM MES buffered saline (pH 5.5) for twenty-four hours. The solution was decanted
and then the leaflets were then crosslinked further in 30 mM EDC and 6 mM NHS
solution in 50mM MES buffered saline (pH 5.5) for 24 hours. Following fixation, valves
were placed in 20% isopropanol in 50 mM HEPES buffer (pH 7.4) for at least six days.
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4.2.2

Differential scanning calorimetry

Differential scanning calorimetry (DSC) was used to measure the thermal denaturation
temperature (Td) of collagen. Samples (3-8 mg) from each of the TRI and GLUT groups
were carefully cut from generally the same region of the leaflet, blotted dry, and placed
flat in hermetically sealed pans.

Samples were tested using a DSC 2920 (TA

Instruments, Newcastle, DE). A pilot run verified the Td range for GLUT compared to
previous results, and the remainder of samples were equilibrated at 20 ºC, and heated at
10 ºC/min. The denaturation temperature was recorded as the maximum value of the
endotherm peak.

4.2.3

Resistance to enzymatic treatment

4.2.3.1 Resistance to collagenase and elastase
BP sheets were cut into 1cm x 1cm patches, rinsed in nanofiltered water, blotted
dry, frozen, lyophilized, and weighed. BP patches were incubated in 1.2 mL of 5 U/mL
porcine pancreatic elastase (Elastin Products Co. Inc., Owensville, MO) in 100 mM Tris,
1mM CaCl2, 0.02% NaN3 (pH 7.8) for 24 hours, or 75 U/mL collagenase (Type I, Sigma,
St. Louis, MO) in 50 mM Tris, 10 mM CaCl2, 0.02% NaN3 (pH 8.0) for 48 hours at 37oC
while shaking at 650 RPM. Enzyme liquid was saved for further studies, digested BP
patches were rinsed in nanofiltered water, blotted dry, frozen, lyophilized, and weighed.
Percent weight loss was calculated. For storage studies, samples were stored for 60 days
in 0.2% glutaraldehyde solution (GLUT samples) or 20% isopropanol in HEPES buffer
(TRI samples), taken out of storage, washed in saline 3x for 15 minute, and challenged
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with the aforementioned protocol with collagenase or elastase and percent weight loss
calculated.

4.2.3.2 Resistance to GAGases
BP sheets were cut into 1cm x 1cm patches and thoroughly washed in 100 mM
ammonium acetate buffer (AAB) at pH 7.0 3x for 5 minutes. BP patches were incubated
in 1.2 mL GAG degrading enzyme solution (5 U/mL hyaluronidase (Sigma, St. Louis,
MO), 0.1 U/mL chondroitinase (Sigma, St. Louis, MO) in 100 mM AAB, pH 7.0) or in
AAB. Samples were shaken vigorously for 24 hours at 37oC. Following 24 hours
incubation, BP patches were washed in distilled water 3x for 5 min, frozen, and
lyophilized. Total hexosamine content was measured using the hexosamine assay as
previously reported [172]. Elson and Morgan’s modified hexosamine assay was used to
measure GAG-related hexosamines. Lyophilized GAG digested samples were weighed,
digested in 2 mL 6 N HCl (24 hours, 96 degrees C), and dried under nitrogen gas.
Samples were resuspended in 2 mL 1M sodium chloride and reacted with 2 mL of 3%
acetyl acetone in 1.25 M sodium carbonate. Ethanol (4 mL) and Ehrlich’s reagent (2 mL,
0.18M p-dimethylaminobenzaldehyde in 50% ethanol containing 3N HCl) were added,
and solutions left for 45 min to allow the color to develop. A pinkish-red color is
indicative of tissue hexosamine quantities, and the absorbance was read at 540 nm. A set
of D(+)-glucosamine standards were used. For storage studies, samples were stored for
21, 60, or 180 days in 0.2% glutaraldehyde solution (GLUT samples) or 20% isopropanol
in HEPES buffer (TRI samples) taken out of storage, washed in saline 3x for 15 minute,
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taken out of storage and challenged with the aforementioned protocol with collagenase or
elastase and percent weight loss calculated.

4.2.4

Suture pull-out test

BP patches were evaluated for structural integrity and its ability to resist tearing.
GLUT and TRI BP patches were cut with a die in rectangular 40 mm x 4.0 mm sections.
Sections were then treated with collagenase, GAGase (combination of enzymes to
degrade GAGs), porcine pancreatic elastases, or no enzyme treatment (8 groups, n = 8).
One side of tissue samples was attached to a bottom clamp in a tensile tester (MTS,
Minneapolis, MN). A single suture (Polypropylene blue monofilament 4-0 P-3
Ethicon™, San Lorenzo, Puerto Rico) was pierced through the sample a third of the way
down the sample and was clamped to the top clamp. Samples were tensile tested at 12
mm/min to determine the amount force it took to pull the suture out of the sample. With
the peak load, thickness of the sample and width were used to calculate cross sectional
area to determine stress.

4.2.5

Mechanical Characterization

We presort the native BP using the pSFDI technique [189] to determine the direction of
collagen fiber alignment. The specimens were cut so that the preferred direction (PD) of
the collagen fibers and cross-preferred direction (XD) are aligned to the two testing axes.
Similarly, the mechanical properties before and after static strain were determined using a
custom built biaxial testing device [190], and analyzed using a method presented in
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Zhang et al. [191]. TRI or GLUT BP patches were cut into a 20mm by 20mm square for
mechanical characterization. A maximum load of 1000kPa was used during testing to
ensure all collagen fiber crimping were straightened. Each specimen was first
precondition under equibiaxial stress for 15 cycles each with a duration of 16 sec. The
specimens were tested for 8 continuous cycles with different loading ratios (1:4, 1:2, 1:1,
2:1, 4:1) with the last one taken as representative.
After initial biaxial tensile testing, each patch was loaded into a custom clamp
system that held the patch in a static strain position at 20% past nominal length in either
the PD or XD direction. The change in geometry that occurred at the 2 week and 4 week
mark were determined using 4 fiducial markers attached to the center of the specimen
[192]. 3 specimens were tested with PD alignment for mounting and 7 specimens for the
XD-alignment for GLUT. 5 specimens were tested for PD-alignment and 3 specimens
were tested for XD-alignment for TRI. The testing was done at room temperature and
immersed in phosphate buffered saline.

4.2.6

Free amine content assay

The primary amine group concentration of tissue samples was determined using a
colorimetric assay previously used to study carbodiimide crosslinking [193, 194]. GLUT
or TRI BP patches were exposed to a solution of NaHCO3 (2 wt%, pH 9.0, Aldrich, The
Netherlands) and 2,4,6 trinitrobenzene sulfonic acid, TNBS (0.5 wt% Fluka,
Switzerland). The reaction was continued for 4 h at 40 oC, after which the samples were
rinsed in saline solution using a vortex mixer to remove unreacted TNBS.
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Samples were freeze-dried overnight, after which the dry mass was determined.
Dry samples were immersed in aqueous hydrochloric acid (2 mL, 6 M, 800C, Aldrich,
Zwijndrecht, The Netherlands) until fully dissolved. The obtained solution was then
diluted with deionized water (8ml) and the absorbance was measured at 340 nm (Perkin
Elmer, Fullerton, USA). The concentration of free amine groups was calculated using the
follow equation.

NH2

=

Free amine group content

[mol/g of tissue]

A

=

Absorbance

[unitless]

V

=

Solution Volume

[mL]

ε

=

14600

[mL/mmol cm]

𝓁

=

path length

[cm]

dry weight of sample

[mg]

mtissue =

The obtained values were used to calculate percent change in free amine content before
and after stretch testing.

4.2.7 In vivo calcification model
Following fixation, all tissues were rinsed thoroughly three times in 30 minute
washes of sterile saline, and remained in sterile saline until implantation. Male juvenile
Sprague-Dawley rats were anesthetized by inhalation of 3% isoflurane gas. A dorsal
surgical incision was made, and two subdermal pockets created on either side of the
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sagittal plane. Two BP patches (1 cm x 1 cm) were blotted and positioned to lie as flat as
possible in each of the pockets. One sample was placed per pocket. Incisions were closed
with surgical staples and samples with fibrous capsule still intact were retrieved after 30
days implantation. The BP patches and surrounding capsule were removed from the
subdermal sites. The middle section was saved for histological analysis. The remaining
sections were placed immediately on dry ice, and frozen at -80°C as soon as possible.
Clemson University Animal Research Committee approves all animal use protocols
(AUP) for the experimental models. All animals receive humane care in compliance with
NIH Publication No. 86-23, revised in October 2002.

4.2.8

Mineral analysis

Half samples (without the capsule) from subdermal implantation studies were
frozen, lyophilized, weighed, and acid hydrolyzed in 2 mL 6N Ultrex II HCl for 20 hours
at 96ºC. Samples were dried under nitrogen gas, resuspended in 1 mL 6N Ultrex II HCl,
and centrifuged at high speeds to separate any remaining particles. Samples were diluted
1:50 in nanofiltered water, Calcium and phosphorous content in samples were analyzed
using the Spectro Acros ICP Spectrometer (SPECTRO Analytical Instruments, Kleve,
Germany). Dilution ratios were used to calculate element content of the sample, and
values were normalized to dry sample weight.
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4.2.9

Histology

BP sections were cut, stored in formalin, processed, embedded in paraffin, and
sectioned at 6 μm for light microscopy analysis. A combined staining technique,
Verhoeff’s Elastic Masson’s Trichrome Method, was utilized to visualize and assess
ECM morphology (elastin and collagen) after in vitro enzymatic treatment. Dahl’s
alizarin red stain with light green counterstain was used to visualize calcium deposition
after samples were implanted in vivo; calcium deposits appear red.

4.2.10 Statistical analysis
Results are expressed as means ± standard errors. Statistical analysis was
performed using one-way analysis of variance (ANOVA). Differences between means
were determined using the least significant difference with an alpha value of 0.05.

4.3
4.3.1

Results

Tissue crosslinking assessment

We determined the thermal denaturation temperatures (Td) of the tissue with DSC.
Td has been shown to effectively correlate with tissue collagen stabilization [29]. Both
GLUT and TRI treated BP showed adequate increase in Td (88.08 ± 0.225oC or 88.09 ±
0.488oC, respectively compared to fresh tissue 56± 3.2 oC [29]), suggesting complete
collagen stabilization.
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4.3.2

Enzymatic stability studies

Figure 4-1. Percent mass loss before and after collagenase or elastase treatment of GLUT
or TRI BP to determine resistance to enzymatic degradation. * indicates significant
difference (p < 0.05).
When GLUT or TRI treated BP patches were challenged with type I collagenase,
they exhibited 2.01% ± 0.726 or 2.94% ± 0.104 mass loss, respectively (Figure 1). No
significant difference was detected between GLUT and TRI treated BP indicating that
collagen within the BP was adequately protected from simulated enzymatic degradation
in both crosslinking methods.
When GLUT or TRI treated BP was challenged with porcine pancreatic elastase,
a significant difference was found (8.38% ± 0.520 vs. 4.69% ± 0.491 mass loss,
respectively, p < 0.0002) indicating that elastin within BP was not protected in GLUT
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treated BP but was protected in TRI treated BP from simulated enzymatic degradation
(Figure 4-1).
When GLUT or TRI treated BP was challenged with a GAGase enzyme cocktail,
there was a significant decrease in percent GAGs retained between buffer treated (control
group) and GAGase treated (enzymatic group) GLUT BP samples (59.0% ± 11.35 and
83.0% ± 5.78, respectively). Loss of GAGs was minimal in TRI BP samples. There were
notably less GAGs present in BP tissues than porcine aortic valve leaflets previously
studied [186].
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Figure 4-2. Histological evaluation of collagen and elastin stability in vitro and in vivo in
GLUT or TRI BP. (A) GLUT BP after material fabrication. (B) GLUT BP after 60 days
storage + elastase treatment. (C) GLUT BP after 30 days implantation. (D) TRI BP after
material fabrication. (E) TRI BP after 60 days storage + elastase treatment. (F) TRI BP
after 30 days implantation. Black arrows indicate dark black, purple fibers indicative of
elastin. Collagen is stained dark blue or purple.
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We next determined the storage stability (60 days) and in vivo resistance (30 days
subdermal implantation) of GLUT or TRI treated BP patches stored in 0.2% GLUT or
20% ispropanol respectively. When GLUT or TRI BP were challenged with collagenase
after 60 days storage, both did not exhibit any detectable mass loss at either time point
from t = 0 days. However, when GLUT BP was challenged with elastase after 60 days of
storage, degradation of elastin was noted by the absence of dark, purple fibrous network
(Figure 4-2B) that were present before storage (Figure 4-2A). Elastase treatment or
storage for long periods of time also seemed to alter the collagen structure as noted in the
different color of the staining. After implanting GLUT BP for 30 days, the dark black,
purple fibrous network was absent suggesting that the host response elastase was also
able to degrade the elastin (Figure 4-2C). TRI BP retained this dark purple, black fibrous
network both after long term storage with enzymatic challenge and implantation (Figure
4-2E and 4-2F) compared to before storage and implantation (Figure 4-2D).
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4.3.3

Resistance to tearing

Figure 4-3. Peak stress to cause rupture in GLUT or TRI BP materials treated with no
enzyme, collagenase, elastase, or GAGase. * indicates significant difference (p < 0.05).
A suture pull-out test was used to evaluate the biomaterial’s ability to resist
tearing. Before enzymatic treatment with collagenase, GAGase, or elastase, GLUT BP
took significantly less peak stress to cause rupture than TRI BP (2943.5 ± 170.27 kPa and
4689.7 ± 201.00 kPa, respectively, Figure 4-3). This data suggests that the TRI treatment
protocol produced an inherently more durable material due to the difference in chemistry.
After treatment with collagenase, GLUT BP took significantly less peak stress to cause
rupture than TRI treated BP (2031.3 ± 312.50 kPa and 5125.0 ± 250.21 kPa, respectively,
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Figure 4-3). After treatment with GAGase, GLUT BP took significantly less peak stress
to cause rupture than TRI BP (2536.5 ± 281.27 kPa and 4649.10 ± 146.46 kPa,
respectively, Figure 4-3). After treatement with elastase, GLUT BP took significantly
less peak stress to cause rupture than TRI treated BP (2653.1 ± 215.22 kPa and 4757.3 ±
276.90 kPa, respectively, Figure 4-3).
Across all enzymatic treatment groups, GLUT treated BP exhibited significantly
less peak stress to cause rupture than TRI treated BP. However within GLUT or TRI
treated BP, enzymatic challenges produced no significant changes in peak stress to cause
rupture when compared with the no enzymatic treatment group within GLUT or TRI.
There was a noted trend of decreased stress to cause suture rupture between untreated
GLUT BP and collagenase treated GLUT BP, however, there is no significant difference
(p < 0.133).

4.3.4

Biaxial tensile testing

Figure 4-4. Mechanical characterization of GLUT or TRI BP materials. (A) Biaxial
tensile testing of GLUT or TRI BP in preferred (PD – with collagen alignment) or
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nonpreferred (XD – orthogonal to collagen alignment) direction. (B) Factor change in
gauge length () before and after static strain testing in different direction static strain for
GLUT or TRI BP. No permanent set (ideal ) is 1. Orientation of PD and XD directions
are indicated in (A). * indicates significant difference (p < 0.05).
Biaxial tensile testing showed that GLUT BP was less compliant than TRI BP in
both the preferred (PD) and nonpreferred (XD) orientations after material fabrication
(Figure 4-4A).

4.3.5

Permanent set results

Data from the stretch test shows that significant permanent set has occurred after
4 weeks for the GLUT group but not for the TRI group. Minimal shear was observed
from the deformation gradient determined from the bilinear interpolation of the markers
(<0.02). The 2 stretch components (PD and XD) of each of the each of the 4 groups (PD
aligned GLUT, XD aligned GLUT, PD aligned TRI and XD aligned TRI) are shown in
Figure 4-4B. The results show that the PS in the direction of mounting for GLUT is
significantly different from the TRI (p 0.0247). Also, we observed no difference in the
permanent stretch between PD mounting and XD mounting. We also observed a small
amount of permanent set in the direction orthogonal to the direction of mounting. This
appears to be due to flattening of the edges of the tissue under the clamps, which caused
the tissue to spread. It's also important to note that the permanent set for TRI is
statistically indistinguishable from this artifactual set effect.
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Mechanical characterization shows that the TRI cross-linking better preserves the
mechanical extensibility of the pericardium (Figure 4-4B). The TRI cross-linking method
shows an extended toe region in comparison to the GLUT, but the maximum tangent
modulus does not appear to be significantly changed. This is opposite of the permanent
set results where GLUT showed more permanent set despite being stiffer.

4.3.6

Free amine content analysis

Free amine content is indicative of the number of free amine groups left
uncrosslinked in the tissue after chemical treatment therefore free amine content can be
used as a metric for effectiveness of crosslinking. Free amine was determined using
TNBS assay before and after the stretch test. GLUT BP showed a significantly increased
percent free amine content than TRI BP when patches were subjected to static strain
testing for four weeks (15.7% ± 3.70 and –2.0% ± 3.35, respectively). The negative
values associated with TRI BP free amine content change indicates that, on average, TRI
BP decreased free amine content after the stretch test.
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4.3.7

Resistance to in vivo calcification

Figure 4-5. Histological assessment of GLUT or TRI BP after 30 days in vivo
implantation. (A) GLUT BP unimplanted. (B) GLUT BP post 30 day implantation. (C)
TRI BP unimplanted. (D) TRI BP post 30 day implantation. (E) Mineralization content in
explanted BP patches. Calcification deposits are stained red and background is
counterstained green. * indicates significant difference (p < 0.05).
Alizarin red staining on GLUT BP showed no calcification before implantation
and heavy calcification after 30 days implantation (Figure 4-5A and 4-5B, respectively).
Alizarin red staining on TRI treated leaflets showed no calcification before implantation
and no calcification after implantation (Figure 4-5C and 4-5D, respectively). This is
consistent with quantitative mineral analysis on explanted GLUT or TRI BP which
indicated significantly more calcium (120.7 ± 18.34 µg/mg dry tissue and 25.3 ± 2.98
µg/mg dry tissue, respectively, Figure 4-5E) and phosphorus (70.3 ± 3.44 µg/mg dry
tissue and 14.3 ± 1.47 µg/mg dry tissue, respectively, Figure 4-5E) content in GLUT BP
compared to TRI BP.
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4.4
4.4.1

Discussion

Comparison of GLUT crosslinking to TRI crosslinking chemistry

It has been previously reported that a significant percent of failed valves show
degeneration and tears but no calcification while other failed valves show heavy
calcification making valves stiff and incompetent but without tissue tears [97, 177]. Both
these failures may be due to improper stabilization of ECM by glutaraldehyde. Schiffbase aldehyde chemistry of glutaraldehyde based crosslinking is initially reversible and
susceptible to hydrolysis [84, 142]. GLUT crosslinking also creates bonds of variable
length between amine groups on collagen that are reversible. Therefore, there is constant
exchange of free aldehyde residues throughout the material. If subjected to loading, it
would be expected that these bonds are hydrolyzing and reforming in different
orientations at an accelerated rate resulting in permanent mechanical deformations as
observed in the current study. The initial instability of glutaraldehyde crosslinking and its
inability to crosslink anything else other than collagen could all be playing a pivotal role
leading to these permenant mechanical deformation that could cause structural
degradation. We report that after simple static strain testing, GLUT BP shows an increase
in free amine content indicating that there are more free amine groups suggesting that
schiff base bonds are being broken after static strain or proteins like collagen/elastin are
broken down. We show in Figure 4-4B that simple static strain can produce permament
geometric deformation or permanent set resulting in the loss of extensibility in GLUT
BP. These results compare well with previously reported data showing that
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glutaraldehyde treated PAV leaflets subjected to cyclic loading undergo permenant
mechanical deformation that alters the shape of the valve resulting in “droopy” leaflets
that cause stress concentrations to develop that could potentially lead to tearing and
altered hemodynamics [96].
TRI crosslinking uses carbodiimide chemistry that creates an amide bond between
amine and carboxyl groups in proteins that is irreversible [153]. We report that there was
no significant percent change in free amine content in TRI BP. Therefore, with TRI,
permanent set effects observed in GLUT BP would not be expected to occur. Our data in
figure 4-4B supports this. More interestingly, Figure 4-4A suggests that TRI BP is also a
more compliant biomaterial than GLUT BP yet TRI BP is able to retain its extensibility
after static strain. This is a bit counter intuitive in that we have produced a material that is
more durable (Figure 4-3 and Figure 4-4B) yet is more compliant (Figure 4-4A) simply
by changing the crosslinking technique from a reversible reaction to an irreversible
reaction.
The GLUT BP showed extensive deformation due to permanent set as predicted.
Although none of the specimen reached the applied stretch of 1.2, this is likely a result of
the process not reaching completion due to the relative short duration of the experiment.
The TRI treatment showed no statistical difference with the non-extended directions. As
previously mentioned, we observed some deformation as a result of the flattening of the
tissue underneath the clamps. This artifactual deformation may be partially responsible
for the observed deformation of the TRI. Thus, the ability of the TRI method to resist
permanent set may be better than the results indicate. The lack of directional differences
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is as expected. The strains observed for the permanent set is in the toe region where no
collagen fibers are straightened. Therefore, the mechanical response in this region is
mainly determined by the non-fibrous matrix, which based on our current understanding
is essentially isotropic. As such, permanent set is also expected to be isotropic, which
also offers greater emphasis on stabilizing the non-collagenous matrix to resist permanent
set.
Developing a material that is more resistant to permanent mechanical deformation
after cyclic or sustained loading may produce a more mechanically durable material that
can resist structural degradation. If extrapolated to constant cyclic fatigue instead of set
static strain, it would be expected that the permanent set process would accelerate and
produce even more alteration than the original shape at implantation leading to stress
concentration build up. This could result in accelerated microtearing and eventually
visible tears that are seen in structurally degraded explanted heart valves. If the initial
deviations in stress concentrations resulting in stress shunting to cause these microtears
can be prevented, then it may drastically reduce structural degradation in BHVs from a
materials standpoint. TRI is in essence a method to produce a stable chemical structure of
the material that fundamentally curbs structural degradation at the micro- and macrolevel.
Furthermore, glutataraldeyde does not stabilize important components of the
tissue such as glycosaminoglycans (GAGs) and elastin [172, 186, 187]. The loss of
unstabilized GAGs and elastin may further exacerbate the process of structural
degradation in GLUT BP. It has been previously established that these two ECM proteins
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play roles in the biomechanical response [15, 18, 27] as well as direct fiber fiber
orientation [27].
It has previously been shown that the collagen in glutaraldehyde treated PAV
leaflets subjected to cyclic loading start to degrade and the overall tissue composite loses
flexural compliance [29]. A loss in glycosaminoglycan (GAG) content was noted in
cycled tissues in the same study. In Figure 1B, there seems to be a trend of GAG loss in
GLUT BP, though not significant. It should be noted that BP tissue in general does not
have a pronounced GAG content as PAV leaflets do.
Previous literature has also noted GLUT treatement of PAV tissues does not protect
against elastin degradation in both in vitro elastase challenges [172, 186] as well as after
in vivo implantation [170, 186]. In Figure 4-1A, Figure 4-2B and 4-2C, we reconfirm that
glutaraldehyde fixation (GLUT) of BP does not protect against elastin degradation.
However, bovine pericardium tissue treated with TRI showed better ECM stability in the
current study and results were similar to what was observed for TRI cross-linked PAV
leaflets [186]. Figure 4-1, Figure 4-2E, and Figure 4-2F clearly demonstrate the
rentension of GAGs and a robust fibrous elastin network similar to freshly treated
samples that is not present in GLUT BP.
GAG stability was imparted by addition of neomycin in crosslinking process as a
HAase inhibitor to prevent GAG degradation. It has been demonstrated that neomycin
protect GAGs within the ECM [159, 160, 172, 186-188]. Neomycin also acts as a
network extender as it has five free amine groups for binding. Therefore, the use of
neomycin in conjunction with carbodiimide not only produces a more irreversible
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crosslinking scheme for ECMs in TRI BP but also a more extensive crosslinking
network. The addition of PGG further stabilizes collagen as well as elastin (Figure 4-1
and 4-2) and has previously been shown to aid in calcification resistance [34, 113, 186].
Figure 4-5 shows that this resistance to calcification is retained in TRI BP.
Glutaraldehyde crosslinking itself has been linked to BHV calcification [107-109, 149,
172, 186] and Figure 4-5 conclusively shows that GLUT BP is predisposed to heavy
calcification, while TRI treated tissues resist calcification.

4.4.2

Implications of TRI to BHVs

Currently, there are over 300,000 heart valve replacements a year globally [1] but
there could be as many as 2MIL+ individuals throughout the world that need a HVR this
very instant [4] with a significant portion of this patient demographic that come from
emerging markets such as India, China, Brazil, Southeast Asia, and Africa [3, 4].
Furthermore, this younger patient demographic falls outside of the design parameters
current BHVs have been fundamentally targeted towards. It has previously been
established in the literature that glutaraldehyde fixed BHVs experience significantly
higher failure rates in younger patients [8]. The main segment of the emerging market
patient demographic is younger and needs durable valves. The alternative crosslinking
TRI method described here can be used to chemically treat tissue biomaterials for BHVs
to produce a biomaterial that resists calcification and structural degradation. More
durable BHVs would minimize recurrent surgeries, improve quality of life for patients,
require no anticoagulants, and would augment current BHV products. Altering chemical

144

fixation techniques to fabricate BHVs would require relatively minimal switching costs
to the manufacturing process to produce BHVs. It would require little surgeon reeducation or user education and can use currently existing instrumentation and
manufacturing assets.

4.4.3

Limitations of study

This study was focused on permanent set based on static stretch tests. In reality,
valve tissue would undergo cyclic fatigue. We, however, hypothesize such cyclic fatigue
would cause even more material changes in GLUT BP. We also used enzymatic
challenges in vitro to mimic in vivo situations. Our methods may be harsher than what is
observed in vivo. Such damage would take multiple years of implantation. The subdermal
calcification study clearly shows that TRI tissues are less prone to calcification; however,
we need to test these tissues as heart valve implants in circulatory environment in larger
animals to study calcification.

4.5

Conclusions

The data suggest that TRI may be a better biomaterial fixative for BHV fabrication
because it stabilizes the ECM as a whole at the chemical level with irreversible chemistry
that prevents micro and macro deformations which may be the underlying driver behind
structural degradation. GLUT exhibited permanent set effects and it may be due to the
reversibility of its inherent chemistry. TRI BP also resisted in vivo calcification seen in
GLUT BP. This research may lead to a novel chemical fixation technique that can be
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adopted by industry to produce a more durable BHVs that can be used to expand the
market of BHVs for younger populations.
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CHAPTER FIVE
5

SPECIFIC AIM 3: MECHANISMS OF CALCIFICATION IN

BIOPROSTHETIC HEART VALVE MATERIALS IN SUBCUTANEOUS RAT
CALCIFCATION MODEL

5.1

Introduction

Over 300,000 heart valve replacements occur each year within the US alone [9].
Under served markets in emerging economies could have as many as 2MIL+ patients
needing replacements right this instant that are predominantly in the young patient
segment [4]. The preferred option for heart valve replacement is bioprosthetic heart
valves (BHVs). The use of BHVs within the US has increased from 37.7% in 1998-2001
to 63.6% in 2007-2011 [10]. The 50% failure rate in BHVs within recipients aged 60-75
is 18.5 years however the 5% failure rate is around 10-12 years from calcification and
structural degradation [1, 2, 5, 79, 98, 177]. Younger patient demographics exhibited
accelerated failure rates [7, 8].
Major barriers to addressing calcification and structural degradation in BHVs are in
a limited understanding of the mechanisms of these failure modes. Though it has been
established historically in literature that calcification is a passive process of calcification
beginning from nucleation sites at cellular debris left in BHV materials [107-110], it is
currently unknown as to how and why these nucleation sites manifest, how they
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aggregate into stenosis inducing calcification nodules, and how the host cellular response
can affect the rate in which mineralization can occur.
From the literature, it seems that there are four factors that contribute to
calcification: (1) high affinity sites for calcification such as phospholipid rich cellular
membranes in devitalized cells or degraded ECM proteins like collagen and elastin [107110, 125, 148, 149], (2) host cellular response both inflammation and immune responses
[134, 135], (3) glutaraldehyde crosslinking itself predisposing the material to calcification
[85, 109, 110, 138, 139, 152], and most recently investigated (4) the role of oxidative
stress on implant integrity [119]. From the literature, it is unclear as to what the major
driving factors are, how they contribute, and the mechanism in how all these driving
factors interact together to produce BHV failure.
Previous literature has reported a chronic, sustained host cellular response after
implantation of glutaraldehyde (GLUT) treated biomaterials in subdermal rat
calcification models [107-110, 112, 137, 172, 186] and sheep orthotopic or human
explants [85, 134, 138]. It has also been previously shown that collagen sponges treated
with GLUT calcify without the presence of cellular debris [108, 109]. We have also
previously demonstrated that biomaterials with cellular debris still present but treated
with an alternative crosslinking chemistry yields a calcification resistant material [172,
186]. In all previous instances, a chronic inflammatory response accompanied by
encapsulation was reported however cellular populations were not investigated nor was
the focus of these studies trying to study exact triggers for calcification.
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Furthermore, it has been previously shown that GLUT treated biomaterials for
BHVs have the propensity to heavily calcify [108-110, 172, 186]. In the current study we
confirm GLUT BP heavily calcifies in a subcutaneous rat calcification model and also
show that even when this calcification prone material is isolated (isolated GLUT BP)
from direct host cellular contact and sustained chronic inflammation response using an
isolation chamber, it still calcifies. Furthermore, we use a novel BHV biomaterial
fabrication protocol (TRI) that utilizes carbodiimide based chemistry coupled with
neomycin and pentagallylol glucose [186] that has previously been shown to significantly
reduce calcification to show that even in the presence of devitalized cells, acute
inflammation with profuse cellular infiltration, sustained chronic inflammation, and
accompanied by high levels of oxidative stress.
Progressive time points were used to examine inflammation response and
advanced glycation end products (AGEs) as it relates to calcification. It was found that
slowing or preventing inflammation of host cellular infiltration into implant was only
effective at delaying onset of calcification. The data also suggests that an exponential
ramping response occurs before heavy onset of calcification and the slowing of this
ramping response may be the key to calcification resistance and prevention. The only
correlation found with significant decrease of calcification was by use of an irreversible
chemistry (TRI) to crosslink the initial biomaterial. These data suggest that the
underlying, main driving factor in BHV biomaterial calcification is the inherent, unstable
crosslinking chemistry of glutaraldehyde itself that lends the BHV biomaterial open to
degradation and subsequent calcification.
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5.2
5.2.1

Methods

Fabrication of tissue based biomaterials

Bovine pericardium (BP) was sourced from a third party arbiter delivered on
0.9% saline and ice to the laboratory. BP sacs were cut into flat sheets and were washed
in 0.9% saline for 15 minutes. BP sheets were then treated with two different chemical
treatment techniques: (1) GLUT – control and (2) TRI – novel, more irreversible
crosslinking technique.
GLUT: BP sheets were treated with 0.6% glutaraldehyde in 50 mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered saline (pH 7.4) at room
temperature with gentle shaking for 24 hours, solution decanted, and replaced with 0.2%
glutaraldehyde in 50 mM HEPES buffered saline (pH 7.4) and the crosslinking was
continued for at least six days [195].
TRI: BP sheets were treated with 0.5 mM neomycin trisulfate solution in 2-(Nmorpholino) ethanesulfonic acid (MES) buffer for 1 hour. The solution was decanted and
leaflets were then incubated in a 30 mM 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC) and 6 mM N-hydroxysuccinimide (NHS) / 0.05% PGG solution in
50 mM MES buffered saline (pH 5.5) for twenty-four hours. The solution was decanted
and then the leaflets were then crosslinked further in 30 mM EDC and 6 mM NHS
solution in 50mM MES buffered saline (pH 5.5) for 24 hours. Following fixation, valves
were placed in 20% isopropanol in 50 mM HEPES buffer (pH 7.4) for at least six days.

150

5.2.2

Isolating GLUT BP from host cellular response

1.5 cm wide dialysis tubing with MW pore cutoffs at 12.5kDa were carefully cut
into 4cm strips. One edge of the dialysis bag was sealed using bioglue ( ) then rolled over
twice and further sealed under pressure with bioglue. A 1cm x 1cm GLUT BP patch was
then inserted into the dialysis bag. The same procedure was then used to seal the
remaining open edge. Isolation chamber design was first tested with albumin solution to
observe if high MW albumin (3 g/ml BSA solution) could traverse the bag. BSA assay
confirmed that no BSA was able to penetrate into the bag. It was then assumed that cells
could not penetrate into isolation chamber because cells are much larger than albumin.

5.2.3 In vivo calcification model
Following fixation, all tissues were rinsed thoroughly three times in 30 minute
washes of sterile saline, and remained in sterile saline until implantation. Clemson
University Animal Research Committee approves all animal use protocols for the
experimental models. All animals receive humane care in compliance with NIH
Publication No. 86-23, revised in October 2002. Male juvenile Sprague-Dawley rats were
anesthetized by inhalation of 3% isoflurane gas. A dorsal surgical incision was made, and
two subdermal pockets created on either side of the sagittal plane. Cusps were blotted and
positioned to lie as flat as possible in the pocket. A 1cmx1cm GLUT BP or TRI BP or
enclosed GLUT BP was placed per pocket. Incisions were closed with surgical staples
and samples with fibrous capsule still intact were retrieved after 1, 3, 5, 7, or 30 Days
implantation. The patches with surrounding capsule were removed from the subdermal
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sites. The middle section was saved for histological analysis. The remaining sections
were placed immediately on dry ice, and frozen at -80°C as soon as possible.

5.2.4

Mineral analysis

Sections of GLUT, TRI, or enclosed GLUT BP patches (without capsule) from
subdermal implantation studies were frozen, lyophilized, weighed, and acid hydrolyzed
in 2 mL 6N Ultrex II HCl for 20 hours at 96ºC. Samples were dried under nitrogen gas,
resuspended in 1 mL 6N Ultrex II HCl, and centrifuged at high speeds to separate any
remaining particles. Samples were diluted 1:50 in nanofiltered water, Calcium and
phosphorous content in samples were analyzed using the Spectro Acros ICP
Spectrometer (SPECTRO Analytical Instruments, Kleve, Germany) at Clemson
University Agricultural Service Laboratory.

Dilution ratios were used to calculate

element content of the sample, and values were normalized to dry sample weight.

5.2.5

Histology

Radial cross sections were taken from the center of explanted BP patches, stored
in paraformaldehyde, processed, embedded in paraffin, sectioned at 6 μm, and stained for
light microscopy analysis. Dahl’s alizarin red stain with light green counterstain was used
to visualize calcium deposition in implanted samples; calcium deposits appear red.
Hematoxylin and eosin (HE) staining was used to visualize and assess the cellular
response to implants. Immunohistochemistry (IHC) was used to detect macrophages
(CD68, AbD Serotec, Raleigh, NC), oxidative stress indicators (CML, ).
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Briefly, sections were rehydrated and subjected to 40 minutes at 95oC of antigen
retrieval in a sodium citrate antigen retrieval buffer (). Samples were rinsed in distilled
water then washed in Tris-Tween 20 wash buffer pH 7.4. An peroxidase inhibitor was
used to block endogenous enzymes (Enzo IHC kit, , ). Samples were then blocked with
0.1% BSA in Tris-Tween 20 wash buffer for 20 minutes. Primary was added at 1 ug/uL
and incubated at 4oC overnight. Samples were washed in PBS wash buffer then incubated
in linker solution (Enzo IHC kit, , ) for 20 minutes. Samples were then washed in PBS
wash buffer then incubated in tracer solution (Enzo IHC kit, , ) for 20 minutes. Samples
were then washed in PBS wash buffer then DAB (Enzo IHC Kit, , ) was applied for 2-5
minutes. Samples were then dehydrated, cover slipped, and imaged for analysis.

5.3
5.3.1

Results

Inflammation response to implants

GLUT BP and TRI BP exhibited cellular infiltration throughout the duration of
the implantation. Initial acute inflammation resulted in profuse cellular infiltration into
both GLUT and TRI BP throughout the entire implant by Day 3 (Figure 5-1A and 5-1C).
Thin fibrous capsules started to form around the implant a several cell layers thick by this
time. As chronic inflammation started to set in by Day 5 and 7, this infiltration subsided
and a noted thicker fibrous capsule around implants were formed with sustained cellular
response quarantining around the implant (Figure 5-1A and 5-1C). During this time, the
previous cellular infiltration seemed to recede away. By Day 30, a drop in cellular
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infiltration was noted samples were surrounded by heavy chronic inflammation response
and fibrous capsule (Figure 5-1A and 5-1C).

Figure 5-1. Gross histological of progression and comparison of host cellular response in
and around GLUT BP, isolated GLUT BP, or TRI BP implanted subcutaneously into
juvenile rats for 1, 3, 5, 7, or 30 days. (Row A) GLUT BP. (Row B) Isolated GLUT BP.
(Row C) TRI BP. All staining is hemotoxylin and eosin. Nuclei are stained purple and
cytoplasm is stained pink. Calcification nodules are granular and stained deep purple. n =
4 per time point per group.

Isolated GLUT BP samples showed little to no infiltration by cells throughout the
time points (Figure 5-1B). However, there was capsule formation with a sustained
chronic inflammation response around the isolation chamber itself (not pictured) but not
the implant indicating that the implant was not in direct contact with a sustained host
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inflammatory response. It was only exposed to interstitial fluid exchange containing
compounds under 12.5kDa.

5.3.2

Qualitative and quantitative assessment of calcification in implants

GLUT BP exhibited spotted calcification by Day 3 or 5 starting in the medial part
of the implant (Figure 5-2A). By Day 7, this calcification started to accumulate and
radiate outward to the edges of the implant. By Day 30, the implant was fully calcified
(Figure 5-2A). ICP confirms this exponential aggregation of calcification (Figure 5-3).

Figure 5-2. Gross characterization of progression and comparison of mineralization in
GLUT BP, isolated GLUT BP, or TRI BP implanted subcutaneously into juvenile rats for
1, 3, 5, 7, or 30 days. (Row A) GLUT BP. (Row B) Isolated GLUT BP. (Row C) TRI BP.
Alizarin red staining for calcification deposits (red) counterstained green. n = 4 per time
point per group.
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Figure 5-3. Quantification of progression and comparison of mineralization in GLUT
BP, isolated GLUT BP, or TRI BP implanted subcutaneously into juvenile rats for 1, 3, 5,
7, or 30 days. (A) Calcium content. (B) Phosphorus content. (C) Inset of calcium content
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for without 30 Day time point. (D) Inset of phosphorus content for without 30 Day time
point. (E) Calcium to phosphorus ratio. n = 8 per time point per group.
Isolated GLUT BP exhibited spotted calcification by Day 5 or 7 starting in the
medial part of the implant (Figure 5-2B). By Day 30, the isolated GLUT BP exhibited
heavy calcification (Figure 5-2B). ICP confirms this exponential growth of calcification
with a ramping response detecting exponential rises in calcification even by Day 1
despite having little cellular infiltration or contact with the host cellular response. There
was a noted delay in the ramping response of calcification and onset to appear in the
histology however, samples still appeared heavily calcified with no significant difference
from GLUT BP in calcium or phosphorus content (100.19 ± 44.32 ug of Ca/mg of dry
tissue and 60.49 ± 23.94 ug of P/mg of dry tissue vs. 120.73 ± 18.34 ug of Ca/mg of dry
tissue and 70.23 ± 3.35 ug of P/mg of dry tissue, respectively) by Day 30 (Figure 5-3A
and 3B).
TRI BP did not exhibit any calcification at any time points (Figure 5-2C). Small
increases in calcium and phosphorus were detected throughout the time points however
there was no significant ramping response of exponential increases in calcium or
phosphorus in TRI BP by day 30 (Figure 5-3). There was significantly reduced
calcification between TRI BP and GLUT BP (25.23 ± 2.59 ug of Ca/mg of dry tissue and
14.34 ± 1.67 ug of P/mg of dry tissue vs. 120.73 ± 18.34 ug of Ca/mg of dry tissue and
70.23 ± 3.35 ug of P/mg of dry tissue, respectively) by Day 30 (Figure 5-3A and 3B).
Interestingly, the ratio of calcium to phosphorus was group dependent. Isolated
GLUT BP and TRI BP exhibited higher levels of Ca:P ratios than GLUT BP at Day 1
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(11.74 ± 6.03 and 27.37 ± 5.48 vs. 1.06 ± 0.22, respectively). However, by Day 30, all
groups (GLUT BP, Isolated GLUT BP, and TRI BP) converged on a Ca:P ratio of 1.72 ±
0.12, 1.65 ± 0.03, 1.76 ± 0.04, respectively.

5.3.3

Macrophage infiltration in to implants

Figure 5-4. Gross histological of progression and comparison of macrophage infiltration
GLUT BP, isolated GLUT BP, or TRI BP implanted subcutaneously into juvenile rats for
1, 3, 5, 7, or 30 days. (Row A) GLUT BP. (Row B) Isolated GLUT BP. (Row C) TRI BP.
All staining is IHC targeting for CD68 (brown). Nuclei are stained purple and cytoplasm
is stained light purple. n = 4 per time point per group.
CD68 (common macrophage marker) was used to detect macrophage infiltration
into the implant. GLUT BP as well as TRI BP showed pronounced infiltration during
Day 1 and 3 (Figure 5-4A and 5-4C). In Day 5 explants, macrophages were notably
occupying the medial region of the implant (Figure 5-4A and 5-4C). By Day 7, sustained
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chronic inflammation response with heavy macrophage presence was apparent around the
implant in the fibrous capsule but the cells seem to recede from infiltration into the actual
implant. This sustained chronic inflammation response persisted until Day 30 (Figure 54A and 5-4C).
Isolated GLUT BP presented with no macrophage infiltration or contact with
macrophages (no fibrous capsules) during the duration of the study (Figure 5-4B).

5.3.4

Advanced glycation end product formation

Figure 5-5. Gross histological of progression and comparison of AGEs presence in
GLUT BP, isolated GLUT BP, or TRI BP implanted subcutaneously into juvenile rats for
1, 3, 5, 7, or 30 days. (Row A) GLUT BP. (Row B) Isolated GLUT BP. (Row C) TRI BP.
All staining is IHC targeting for CML (brown). Nuclei are stained purple and cytoplasm
is stained light purple. n = 4 per time point per group.
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Carboxymethyllysine (CML) was used to detect advanced glycation end (AGE)
product formation. CML was detected in early stages of GLUT, isolated GLUT BP, and
TRI BP samples (as early as Day 3) and staining proceeded to intensify through Day 30
(Figure 5-5). There seemed to be a delay in CML formation in isolated GLUT BP (Figure
5-5B).

5.4
5.4.1

Discussion

Gross cellular infiltration and calcification

Previous literature has established that host cellular infiltration can lead to
compromising of BHV implant materials in both small animal studies [107, 108, 116] as
well as explants from large animals [85, 134, 135, 138, 139]. This cellular infiltration has
been both implicated in ECM fragmentation [134, 135] as well as contributing to the
calcification of BHV materials [107, 108, 116]. It has been previously demonstrated that
damaged ECM proteins such as elastin and collagen can calcify [111, 113, 114, 196,
197].
In the present study, HE staining revealed that all three groups (GLUT BP, GLUT
BP isolated, and TRI BP) elicited a persisting chronic inflammation response resulting in
encapsulation of the implant (Figure 1) with infiltration of cells into the implant. It is
important to note that the GLUT BP isolated group do not have fibrous capsules. It
should be further noted that the isolation chambers did not completely nullify the host
cellular response from the implant in half of the trials. Some cells were able to infiltrate
some GLUT BP isolated samples and others were not able to infiltrate. However, the
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isolation chamber was able to slow down and regress the level of cellular infiltration
compared to GLUT BP that were not isolated. GLUT BP and GLUT BP isolated groups
calcified heavily but TRI BP exhibited significantly lower levels of calcification (Figure
5-2 and 5-3). Interestingly, heavy macrophage infiltration (Figure 5-4) was present
initially in both GLUT BP (calcified heavily) and TRI BP (minimal calcification) with
persistent chronic inflammation encapsulation. Additionally, with minimal cellular
interaction, isolated GLUT BP (GLUT BP has been proven as a calcification prone
material) still was found to calcify by the end of the study.

5.4.2

Acute cellular response

Early onset of acute inflammation response was characterized by host cells
forming 1-3 layers around implant during 1-3 Day time points (Figure 5-1) and
infiltrating into implants with a heavy presence of macrophages (Figure 5-4) in both
GLUT BP and TRI BP samples however the isolated GLUT BP samples did not exhibit
little to no infiltration. This is to be expected as this was the purpose of the isolation
chamber. It seems that infiltration pattern of cells into implants follow negative space
between collagen fibers. Calcification was not detected in any groups via alizarin red
(Figure 5-3) however there are slightly elevated levels of calcification detected via ICP
quantification in the GLUT BP and GLUT BP isolated groups but not in the TRI BP
group (Figure 5-3). These detections in slightly elevated levels of calcification are most
likely early nucleation sites forming and corroborate with previous results that looked at
crystal formation at early time points (24hrs) to detect calcification nucleation sites [108].
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Interestingly, figure 5-3E depicts initial days of calcification present with increased influx
of calcium content then phosphorus levels increased to level out the ratios to that of
calcium rich hydroxyapatite. This suggests that there is initial binding of calcium content
that also attracts more phosphorus content into the tissue. This suggests that devitalized
cells may serve as initial binding sites for calcification but the aggregation of calcific
nodules relies on drawing more phosphorus into the implant.

5.4.3

Transition from acute to chronic cellular response

During 5 and 7 Day time points, chronic inflammation response begins to set in
with more cell layers forming a thicker fibrous capsule, deeper and more aggressive
cellular infiltration into the implant, and formation of foreign body giant cells (FBGCs)
(Figure 5-1) in GLUT BP and TRI BP groups. FBGCs may be infiltrating macrophages
fused together as there was still pronounced macrophage infiltration (Figure 5-4).
Cellular infiltration continues down negative spaces between collagen fibers in GLUT BP
and TRI BP (Figure 5-1). Minimal to no infiltration is present in isolated GLUT BP
samples. Beginnings of onset of calcification was detected via alizarin red (Figure 5-2) in
GLUT BP and GLUT BP isolated groups but not in TRI BP. This data is consistent with
quantification values of calcification via ICP indicative of elevated, ramping levels of
calcium and phosphorus in GLUT BP and GLUT BP isolated groups but small elevations
in TRI BP (Figure 5-3).
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5.4.4

Chronic cellular response

At 30 days, all groups are heavily encapsulated with 10+ cell layers of fibrous
capsule formation and infiltration seems to have receded from the medial portion of the
implant (Figure 5-1). However, host cells persist within the implant and numerous
FBGCs have formed within and around the implant in all GLUT BP and TRI BP groups
(Figure 5-1). Heavy calcification is only present in GLUT BP and GLUT BP isolated
groups (Figure 5-2 and 5-3). Mineralization seems to be delayed in the early onset of
calcification however, even if the cellular presence is hindered or slowed down,
calcification seems to only be delayed noting the no significant change in mineralization
by Day 30 between GLUT BP and GLUT BP isolated groups (Figure 5-3). TRI BP
exhibits minimal calcification (Figure 5-2 and 5-3) despite a persistent chronic
inflammation response (Figure 5-1) with macrophages present (Figure 5-4).
It should be noted that even with little infiltration of cells, isolated GLUT BP
samples still exhibited ramping response of calcification. This suggests that calcification
does not require cellular infiltration into the implant and that the in vivo conditions are
enough to produce calcification. This also suggests that there is something inherently
calcification prone about the biomaterial. Previous data in BHV materials research were
also consistent with these findings [109, 110].
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5.4.5

Underlying mechanisms to calcification of BHV biomaterials

Table 2. Driving factors in BHV failure with regards to calcification.
Triggers for Calcification

Supporting Literature

Devitalized cells serve as nucleation sites that initiate calcification

[107, 108]

Degraded ECM proteins providing high affinity binding sites for [29, 125, 126]
mineral deposition
Mechanical wear and tear over time damages ECM proteins

[29, 93, 96, 97, 99]

Immune and/or inflammatory response degrade ECM that could [134, 135]
lead to calcification of degraded ECM components
Instability of glutaraldehyde Schiff-base bonds are degraded [109, 110, 172, 178, 186]
over time leading to ECM degradation (mainly collagen); does not
stabilize other ECM proteins such as GAGs and elastin
Oxidative stress damaging ECM proteins

[119]

Each hypothesis has compelling data that suggests that all these calcification
models run in parallel and contribute in some way to produce calcification in BHV
biomaterials. The real question is determining which is the major underlying driving
factor(s) that contributes the most to overall calcification.
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5.4.6

Devitalized cellular content and immunogenic/inflammatory eliciting residues

Devitalized cells could be the culprit in nucleation site formation and have previously
been shown to facilitate initial crystal formation on phospholipid rich substrates [107,
108]. However, there have been groups that previously demonstrated that type I collage
gels calcify on their own (completely devoid of cells [109].
However, delipidation techniques such as the use of surfactants and alcohols rid
these nucleation sites but only to a certain extent. Delipidation techniques only delay the
onset of calcification [112, 149]. Also, previously in our lab, other groups, and the
current study, we have shown that alternative treatment techniques such as carbodiimide
based crosslinking result in no calcification despite leaving devitalized cells in the tissue
with host cells infiltrating into the tissue [153, 172, 186].
Others have also postulated that the immune response may also play a role in
calcification and structural degradation of BHVs [134, 135]. It has been previously
shown that there are heavy residual immunogenic markers residing in BHV materials
[135]. However, others have shown previously that implantation of BHV materials in
nude mice (no leukocytes) still calcified suggesting that the immune system plays a small
roll in calcification [109]. In these studies there was a noted presence of macrophages and
FBGCs.
In the current study, we show that there are macrophages abundantly present
throughout the tissue and within the capsule (Figure 5-5) but when attempted to stain
with CD8 and CD80 (T-lymphocyte cell markers), all groups (calcified or not calcified)
did not exhibit significant signaling within the tissue to indicate the presence of these cell
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types (not pictured). This data suggests that though the immune system may demonstrate
the capacity to degrade ECM components, an immune response may not be critical to
calcification. Furthermore, perhaps it is more pertinent to look at the inflammation
response, specifically macrophages, if we are considering that the host cellular response
plays a pivotal role in calcification.

5.4.7

Underlying driving factors of calcification and BHV biomaterials

The more likely explanation in lieu of finding an external culprit to current BHV
material failure modes is perhaps questioning the inherent biomaterial itself, specifically,
its method of fabrication and how stable it truly is. Previously in our lab, we have
demonstrated that glutaraldehyde treated soft connective tissues are not able to stabilize
all major ECM components [172, 186]. Furthermore, glutaraldehyde is not able to
provide stable crosslinking long term to protect the integrity of the tissue composite and
have been implicated in the calcification process itself [85, 139, 152]. Additionally,
techniques that quench the reversible Schiff-base reaction produced by aldehyde
chemistry [85, 138, 139, 152] or replacement of glutaraldehyde with a more irreversible
crosslinking chemistry [153, 159, 186] as well as the current study has resulted in
significant reduction of calcification and ECM integrity.
Oxidative stress has also recently come into playing a role in studying BHV
biomaterial failure. It has been demonstrated that oxidative stress can degrade
glutaraldehyde bonds to such an extent that the collagen is vulnerable to enzymatic
degradation after oxidative stress is applied [119] and thus may provide mineralization
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deposition sites within the high affinity pockets of degraded ECM. Cellular interaction
may exacerbate the levels of oxidative stress indicated by increased presence of advanced
glycation end products (AGEs) that form under increase oxidative stress conditions in
diabetic patients with vascular complications [198, 199] thus further exploiting the
instability of the reversible glutaraldehyde crosslinking. Table 2 summarizes the early
time points in how host cellular activity correlates with calcification and rising oxidative
stress levels in the GLUT BP groups. However, it should be noted that there was still a
high degree of CML detected in TRI BP yet it did not calcify. These data suggest that
though oxidative stress may play a synergistic or accelerating role in calcification, it is
not the root cause of the problem.
Table 3. Qualitative Comparison of GLUT, GLUT isolated, or TRI BP after 1, 3, and 7
days.
GLUT BP
Day 1

Acute
initiated;

GLUT BP isolated
inflammation Acute

TRI BP

inflammation Acute

cellular initiated around isolation initiated;

infiltration initiated

inflammation
cellular

chamber; no infiltration infiltration just starting
into implants

Day 3

Acute inflammation; few Acute

inflammation Acute inflammation; few

cell layer thick fibrous around
capsule formation with chamber;
profuse

isolation cell layer thick fibrous
no

fibrous capsule formation with

cellular capsule formation with profuse
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cellular

infiltration

throughout few cells infiltrating

infiltration

implant
Day 7

Chronic

implant
inflammation Sustained

heavy Chronic

starts to set in; several inflammation
cell layer thick fibrous isolation

receded

chamber;

no cell layer thick fibrous

capsule capsule formation with

cellular formation with few cells receded
infiltrating

Low oxidative stress

Low to no oxidative Low to no oxidative

Escalating

infiltration

stress

oxidative Escalating

stress
Day 7

cellular

infiltration

stress
Day 3

inflammation

around starts to set in; several

capsule formation with fibrous

Day 1

throughout

oxidative Escalating

stress

oxidative

stress

High level of oxidative High level of oxidative High level of oxidative
stress

stress

stress

Day 1

No calcification present

No calcification present

No calcification present

Day 3

Spotted mineralization

No calcification present

No calcification present

Day 7

Medial

calcification Spotted

radiating outward

mineralization No calcification present

medially

and

accumulation
calcification
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edge
of

These data from the current study suggest that calcification can be significantly
reduced even in the presence of devitalized cells, acute inflammation with profuse
cellular infiltration, sustained chronic inflammation, and accompanied by high levels of
oxidative stress. Furthermore, even the isolation of calcification prone biomaterials
(GLUT BP) from direct cellular contact and sustained inflammatory response resulted in
high levels of oxidative stress and calcification. Though devitalized cells may provide
initial nucleation sites and the host cellular response may be able to degrade ECM
proteins as well as oxidative stress may be present, these data suggest that all these
factors are only symptoms of calcification that exacerbate the process.
The only difference in the current study that is different between the groups that
calcified and did not calcify is the method of material fabrication. More specifically, a
more irreversible base crosslinking chemistry that also stabilized all other ECM proteins
was used instead of reversible glutaraldehyde based crosslinking chemistry. Therefore,
these data suggest that the continued use of reversible aldehyde chemistry is most likely
the underlying cause to the failure modes of BHV biomaterials.

5.4.8

Implications in BHV design

It should also be noted that there is convergence of mechanisms behind the two
major failure modes of BHVs – structural degradation and calcification – if we are to
accept all the previous literature published in the BHV research field. Increased structural
degradation leads to higher affinity binding sites for mineralization to occur;
mineralization alters biomechanics such that stress distribution may be shunted to
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concentrated areas which may cause initiation of tearing. All these processes may
synergistically accelerate each other in which design flaws in BHV designs are exploited
in which one mechanism accelerates past the others and becomes the ultimate mode of
failure at the clinical level. What underpins all of this is the inherent biomaterial itself,
specifically the chemistry used to produce it.
Ultimately, all these processes most likely stem from a common upstream design
flaw that allows these mechanisms to propagate – glutaraldehyde fixation during BHV
biomaterial fabrication. Due to the reversibility of GLUT, there is no avoiding these
hazardous mechanisms from occurring because the inherent chemistry is not stable
enough to prevent these failure mechanisms from occurring. It seems the only way to
truly circumvent all these failure modes is to make design changes upstream of the BHV
production process – create a new biomaterial using alternative, more irreversible
chemistries. In the current study, we have confirmed that under the same in vivo
conditions as GLUT BP with cellular infiltration and devitalized cellular content left over
from the fabrication process, TRI BP is able to effectively curb the ramping response in
calcification while undergoing significantly less oxidative stress damage. Table 2
conclusively summarizes that even in the event of high cellular infiltration, more
irreversible chemistries are still able to resist oxidative stress and calcification. Therefore,
more irreversible chemistries should be considered for BHV fabrication.
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5.4.9

Limitations of the study

The isolated GLUT BP chambers were imperfect in that some let in a small
amount of cells. However, there was no CD68 detection (Figure 5-4) and the HE stains
(Figure 5-1) indicated a very minimal amount of cells able to leak into the isolation
chambers. Furthermore, there was no fibrous capsule formation around any of the
explanted isolated GLUT BP samples (Figure 5-1) therefore the implant themselves were
not in any direct contact of a sustained inflammatory response like the other groups of the
study.
CML is only an indirect indicator of oxidative stress because it can form from other
pathways. However, previous literature has shown that it has a high correlation with
oxidative stress [198, 199] and it has also been previously demonstrated that oxidative
stress has been demonstrated to damage BHV biomaterials, specifically collagen [119].
Future studies will aim at determining better metrics to directly measure oxidative stress
as well as other AGE formation and high affinity sites for mineralization.

5.5

Conclusions

Progressive time points were used to examine inflammation response and advanced
glycation end products (AGEs) as it relates to calcification and it was found that slowing
or preventing inflammation of host cellular infiltration into implant was only effective at
delaying onset of calcification. The data also suggest that an exponential ramping
response occurs before heavy onset of calcification and the slowing of this ramping
response may be the key to calcification resistance and prevention. TRI BP even in the

171

presence of devitalized cells, acute inflammation with profuse cellular infiltration,
sustained chronic inflammation, and accompanied by high levels of oxidative stress, was
able to resist heavy calcification. GLUT BP and isolated GLUT BP samples calcified
heavily suggesting that the underlying, main driving factor in BHV biomaterial
calcification is the inherent, unstable crosslinking chemistry of glutaraldehyde itself that
lends the BHV biomaterial open to degradation and subsequent calcification.
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CHAPTER SIX
6

CONCLUSIONS AND RECOMMENDATIONS

New preliminary data from the Vyavahare group has demonstrated permanent set
effects in bovine pericardium (preferred material of use in industry for BHV fabrication)
with glutaraldehyde based crosslinking chemistry however these permanent set effects
were eliminated when using carbodiimide (irreversible crosslinking chemistry that has
been previously demonstrated to resist calcification) in combination with neomycin
(GAGase inhibitor to enable GAG retention) and PGG (stabilizes collagen and elastin as
well as implications in calcification resistance) referred to as TRI. This alternative
fabrication method, TRI, also has been previously demonstrated to enable biomaterials to
retain all ECM components through both in vitro enzymatic challenges as well as small
animal in vivo studies [186]. Furthermore, this material has also been shown to resist
calcification even in a long term implant rat subcutaneous calcification model (commonly
accepted model for biocompatibility and, within the space of BHVs, an accepted
accelerated model to test calcification within biomaterials) [186]. This dual calcification
and structural degradation resistance is suspected to be caused by the irreversible
crosslinking technique protecting the ECM such that it is not susceptible to degradation
and thus eliminates the sites for nucleation sites for calcification nodules to form as
depicted in figure 6-1. This also suggests that calcification and structural degradation
processes in the scope of BHVs are highly intertwined and share a common underlying
factor – the use of reversible chemistry such as aldehydes as a chemical fabrication
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method. Only by innovating around this common underlying factor can we hope to bring
transformative technology to the HVR market.

Figure 6-1. Overview of processes associated with glutaraldehyde or TRI crosslinking
techniques leading to calcification and structural degradation.
Additional recommendations on future research aims include:
The following recommendations are intended to push this technology to market.
Fulfillment of these recommendations are aimed at partnering with a heart valve
producer to push TRI to market.
(1) Further investigation of effects of irreversible chemistry on permanent set
effects with static strain. The data demonstrated that there are irreversible
chemistries that can yield compliant materials that also resist permanent
geometric deformation with sustained mechanical insult at the fundamental level.

174

Even when these materials are subjected to mechanical insult, this extensibility is
retained. Further investigation into the limitations of these biomaterials generated
from irreversible chemistry will distill out insightful material property constants
that can be used as boundaries in building a constitutive model. This entails
testing different set strain conditions mainly including percent stretch and
duration. This also includes quantifying bending stiffness before and after
mechanical insult with static strain at different stretch percentages as well as
crimp testing to look at the effects of prolonged compressive stress on the
differing biomaterials. Crimp testing is paramount to demonstrating the efficacy
of a novel biomaterial because the field of heart valve replacements has been
disrupted by and highly prefers transcatheter delivery of BHVs. Transcatheter
valves are growing much more market share year over year and are quickly
becoming a surgeon preference.

(2) Expanding investigation to simple accelerated, cyclic axial stretching of
material. This investigation would further expand recommendation (1) in which
the mechanical insult is more physiological like in that it is a cyclic mechanical
insult rather than a static mechanical insult. Observing the ECM integrity and any
ECM degradation products through cyclic loading would be more insightful into
the durability of the material of the material and testing the material’s limit in
terms of maintaining integrity and biomechanical properties. Again, data from
chapters 3, 4, and 5 all consistently demonstrate that irreversible chemistries
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incorporated into the fabrication process of BHV biomaterials have the potential
to generate a more biomechanically advantageous material that is also more
durable.

(3) Construct BHV out of glutaraldehyde or novel material and fatigue in vitro
using accelerated wear tester. Accelerated wear testing in industry is commonly
used to test the functional durability of a heart valve replacement before spending
a significant amount of capital on a large animal clinical trial. Usually, accelerated
wear testing can brute force simulate 100s of millions of cycles within months to
ensure valve durability. Building in-house or collaborating with Dr. Simionescu’s
laboratory to design a press fit mold to form tri-leaflet geometries out of
biomaterials produced from our labs out of custom 3-D printed parts is the next
essential step in demonstrating the efficacy of the novel biomaterial fabrication
technique with irreversible chemistry. A custom fatigue tester can be built that
incorporates these custom press fit molds to effectively mount the best geometries
and maintain the highest consistency throughout the study.

(4) Partner with valve producer to execute large animal study using
glutaraldehyde and TRI. Previously, carbodiimide alone did not make it to
industry commercialization efforts. This could have had political reasons for not
making it to market but it is apparent that carbodiimide alone did not present
enough value added for heart valve replacement producers to invest the capital
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expenses, time, and infrastructural switching costs to adopt the new technology.
Getting a more robust irreversible chemistry to large animal preclinical study
would be monumental in demonstrating the efficacy of alternative chemistries for
industrial use especially after the completion of recommendation (3). With
accelerated wear data demonstrating the durability of the BHV coupled with the
physiological data demonstrating biocompatibility and functional efficacy in a
living model that mimick’s what the FDA looks for in validation data is the final
step in proving the efficacy of the novel material itself.

The following recommendations are more towards exploration into the basic science
of how the chemistry affects the biomaterials’ properties. In essence, these studies
seek to answer ‘why does the technology work.”

(5) Impart mechanical insult onto biomaterials and implant in vivo. There still
does not exist a model to investigate the parallel processes at work when a
biomaterial is undergoing structural degradation. Because we have data that
suggests that structural degradation through wear and calcification have a
common pathway, we must study how these two processes affect one another and
what underlying factors inevitably cause failure. By mechanically insulting the
material first then implanting into an animal model and observing the difference
in progression of calcification, we can, at relatively low cost, observe how these
pathways cross talk into synergistic pathways that accelerate valve prosthesis
failure.
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(6) Study oxidative stress effects on the biomechanical properties and durability
of biomaterials fabricated from irreversible chemistries. More in depth
exploration into the effects of oxidative stress as well as the implications of it in
structural degeneration from wear need to be conducted. Previously, it has been
demonstrated that oxidative stress can contribute to structural degradation but
these studies lack looking in depth what this oxidative stress does to macrobody
biomechanics as well as the durability of the material. Looking at suture pull out
strength, biaxial tensile testing with hysteresis, and cyclic loading to observe the
biomaterial’s ability to retain original biomechanics as well as more in depth at a
multitude of byproducts directly produced from oxidative stress damage is
imperative.

(7) Study oxidative stress effects on biomaterials fabricated from irreversible
chemistries in small animal studies. More in depth exploration into the effects
of oxidative stress as well as the implications of it in structural degeneration and
calcification is needed. Previously, it has been demonstrated that oxidative stress
can contribute to structural degradation but these studies lack looking at the in
vivo implications of oxidative stress as well as studying what a biomaterial that
resists oxidative stress behaves like. By imparting oxidative stress damage onto
biomaterials then implanting them into small animals, we can observe the effect
of oxidative stress on the calcification process.
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(8) Time point study to provide more insight into ultrastructure of calcifying
implants. Chapter 5 serves as a basis for a cohesive summary and thus strategic
list of triggers to investigate into calcific structural degradation in BHV materials.
TEM, endogenous protease activity, protein expression, cell population
identification and quantification, and gene expression should be studied to
understand the role of how the proposed processes of calcification summate and
syngergize with one another from the biochemical to functional level to produce
calcification. Furthermore, if we have a material that resists calcification, we can
study which processes are short circuited with these materials which will lead to
the key, pivotal triggers that fundamentally underscore the process of structural
degradation. It should be emphasized that the study of calcification proceede
onward with experimental groups that test both calcification prone and
calcification resistant biomaterials as well as a variable group that isolates one
trigger.
Only through these recommendations can we truly understand the larger picture of
how BHV biomaterials fail and only then can we engineer better, disruptive solutions
rather than marginal increases in technology. Figure 6-2 illustrates an old but still telling
figure in the processes of BHV biomaterial failure.
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Figure 6-2. Model for structural dysfunction in bioprosthetic heart valves. Two
pathways are shown, one induced by stress, resulting in structural degeneration and valve
failure. The other is affected by implant and host factors, results in cuspal calcification
and valve failure. Implant and host factors induce collagen-oriented deposits, seen in the
ultrastructure, and predominate at flexion points and commissures. The pathways are not
independent, however, since structural degeneration predisposes cusps to calcification
[13].
Figure 6-2 clearly shows how we have known that structural degradation through
calcific and non-calcific means have had the same underlying issue – these failure
mechanisms both stem from the same biomaterial from the very beginning. Now that the
research has been done to establish enough data in the two branches causing BHV failure,
it is now time to understand how those processes interplay. We must find where all these
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causes stem from and design from that point. We do have compelling evidence that
structural degradation is a process that has multiple driving factors operating in
parallel that can accelerate the other processes synergistically to produce failure –
the next steps in research should focus on how these driving factors affect one
another so we may narrow down current design flaws and strategically address
those limiting factors in current designs. Figure 6-3 depicts a unified hypothesis in
calcific and non-calcific structural degradation in BHVs.

Figure 6-3. Unified hypothesis tying together structural degradation processes.
This effort of using compounds previously demonstrated to stabilize individual ECM
proteins and prevent calcification in combination with one another may be the new
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approach to engineering the next generation of BHVs that have significantly longer life
span.
The added value proposition of protecting all ECM proteins with an irreversible
chemistry such as TRI from an outcomes standpoint is threefold.
(1) More native like biomechanical behavior and compliancy and retention of more
native like biomechanical behavior and compliancy after cycling or prolonged
strain.
(2) Significant reduction in ECM degradation byproducts as well as known cytotoxic
residues that may augment a negative host cellular response.
(3) Calcification resistant biomaterial.
The added value proposition of innovating a new chemical fixation technique over
innovating another method to fabricate heart valves from an operations standpoint has
some distinct advantages.
(1) Quickly scalable into industry and allows quick adoption because heart valve
producers already have capital assets and infrastructure built out to manufacture
these BHVs.
(2) Predicate devices already exist so regulatory hurdles, distribution, operator and
user education, and payer models can be readily adjusted for market adoption.
(3) Because of (1) and (2), this technology can quickly scale to emerging economies
where this technology is needed most.
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It should be noted that there are other methods of creating heart valves currently
being researched however not yet implemented. Polyurethane valves are the leading
candidate for synthetic based polymer valves however lack durability. Implications of a
successful polymer valve would be a more efficient manufacturing technique from a
batch standpoint and would allow for better scaling as well as functional valve design for
transcatheter valves.
Tissue engineering also poses a unique value proposition because a tissue
engineered heart valve integrate into the human body to give a permanent, ever adapting
solution. However, there are a couple of major obstacles that have prevented this idea
from going forward. Previously, decellularized heart valves have been tested in the early
2000s and because the investigators failed to properly decellularize the ECM, the residual
cellular components caused implant rejection immediately after implantation and resulted
in 3 pediatric deaths and 1 emergency heart valve replacement. This resulted in a huge
political blowback that has regressed the field back to basic science in investigating better
protocols for decellularization. Also, valvular intistitial cells are poorly understood as
well as stem cells in general, especially when it comes to modulating a remodeling
response versus a growth response. From a scaling to emerging markets standpoint,
decellularized valves would be problematic because many countries which are in dire
need of heart valve replacements do not yet have the facilities and infrastructure built out
that would support stem cell harvesting and growing of tissue engineered valves.
Perhaps this scattered approach to produce scientifically viable ideas that are
completely outcomes based and does not consider other parts of operations, supply chain,
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implementation, and payer models underpins the reason why we have only seen marginal
innovations that add onto pre-existing techniques when it comes to industry adaptation of
an alternative to glutraldehyde despite all the shortcomings of the crosslinking. This
phenomenon is not unique only to the very narrow vertical of the HVR market but across
the healthcare industry and technology spaces in general. There has not been a concept
that has demonstrated compelling data from a larger picture perspective to properly
derisk the amount of upfront investment required to bring a class III medical device to
market and justify the switching cost of adopting a different industry standard.
If we are to truly innovate for the betterment of masses and expand to all the
patient segments in need of heart valve replacements, we as innovators within the field of
heart valves must collaborate together to solve the larger puzzle that is BHVs. We cannot
continue to present the market space with tid bits and lone puzzle pieces, though pristine
and compelling within their own right, of the larger picture and expect stakeholders
within a market space that directly affects hundreds of millions of individuals to take a
large risk on an unclear opportunity. We must start from patient clinical needs and
systematically approach preventing the underlying mechanisms of action in calcification
and structural degradation to consider alternative chemistries that may produce
calcification resistant and structurally robust biomaterials. Furthermore, we must subject
these alternative approaches to biomaterial fabrication and valve design to the harshest of
objective criticism from a multi-disciplinary perspective. BHV concepts groomed out of
academia for industrial commercialization must be subjected to as much chemical
stability analysis as biomechanical merit; from molecular merit to macro-biomechanics
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merit. This academic research in basic concept must also be done in parallel and
complete alignment of clinical appointments (from surgeon, insurance, and
administrative level) and business acumen (financial viability, risk assessment, strategy,
target market segmentation, etc.) to adequately depict an opportunity that presents an
undeniable value proposition and is investible and scalable to the market space. Only then
will we have a chance at market adoption and only then are we able to fully use our
skillsets to fulfill why we dedicated our lives to research and innovation in the first place.
To help people who would otherwise have no other option.
Because of there are drastically different clinical needs between the current
developed world market and emerging economy market, there must be changes in heart
valve design to fully capture market share and effectively serve the new patient
demographic in emerging economies. Because the market’s current patient segment
served is predominantly elderly, current heart valve durability and implant lifespan is
engineered only to 10-15 years before failure rates start to occur [1, 7]. Strictly based on
patient age demographic, the current market gold standards for heart valve replacements
will not serve the emerging economy heart valve replacement market because the average
recipient age is ~30 years or half the age of developed economy recipients. The value
proposition offered to the patient segment of the emerging economies by the current
technology available on market only marginally improves lifespan. Furthermore, it has
previously been shown that current heart valve technology fails faster and sooner as
patient age decreases [6, 8]. This implies that the marginal amount of engineering that
must be invested into each additional year of implant life increases as implant life
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increases. Therefore, the much larger patient segment distribution exhibited by emerging
economy patient demographics will not be fully served by commercially available
technology currently and this sector will need technological innovation if it wants to
expand and capitalize on more patient segments. For a replacement valve to effectively
capture market share in these new market segments in emerging economies where most
of the human population resides and where there is the most clinical need, more robust
biomaterials must be designed coupled with computational modeling to optimize heart
valve design such that it has the lowest chances of failure modes at both the base
biomaterial level and device design level.
The basic question to implementing much needed technological advancement in
this sector of healthcare is how we can introduce value proposition to both developed
markets and emerging markets past the cannibalization of current product lines. How can
we design a valve that minimizes current market shareholder losses in adopting new
technology and drive increased value in all the patient segments and geographical
segments. By designing a heart valve with increased implant life in many patient
segments and such that it leverages current heart valve supplier competencies is the
quickest way to market and drives the most social impact.
For the past 50+ years, HVRs shifted from early mechanical models such as the
Bjork-Shiley valves or the ball and cage models to a diversified market space of high
performance designs such as the bileaflet conduit MHVs or the spectrum of proprietary
BHVs in an effort to increase implant life and patient quality of life. However, there is
still room for improvement. MHVs currently require anticoagulant therapy that has many
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dehabilitating side effects for the patient and restricts its use in a younger demographic.
BHVs experience failure rates at 10-15 years after implantation due to calcification and
structural degradation. BHVs also fail faster in younger patients and therefore only serve
an older population. Most technological innovation has taken place in the form of
transcatheter or percutaneous delivery of BHVs however the base concept of a HVR has
not been innovated in recent decades leading to a stagnation in improved patient
outcomes. To design the next generation of HVRs, we must look to redesign the base
biomaterials these HVRs are fabricated out of. Smarter, more durable, more mechanically
optimal, more biocompatible, and more easily implanted designs are needed address the
precipitous need that is demanded of this technology that is largely neglected despite our
technological advances in our lives today. Multidisciplinary collaboration through the
different silos of science and academia as well as consideration of the needs of other
stakeholders in this complex ecosystem such as industry, investors, payers, users,
healthcare providers, healthcare administrators, etc. all must accompany the distillation of
science into a technology platform to be harnessed by society. This is the true essence of
innovation and the HVR market space is in dire need of it.
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